US3625214A - Drug-delivery device - Google Patents

Drug-delivery device Download PDF

Info

Publication number
US3625214A
US3625214A US38237A US3625214DA US3625214A US 3625214 A US3625214 A US 3625214A US 38237 A US38237 A US 38237A US 3625214D A US3625214D A US 3625214DA US 3625214 A US3625214 A US 3625214A
Authority
US
United States
Prior art keywords
drug
delivery device
film
body fluids
comprised
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US38237A
Inventor
Takeru Higuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of US3625214A publication Critical patent/US3625214A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61DVETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D7/00Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time

Definitions

  • a drug-delivery device for prolongedly delivering drugs to patients according to any predetermined time release profile e.g., increasing, decreasing, constant, pulsing, sinusoidal, and like patterns of release, is fabricated by applying a drug coating of varying or uniform thickness to a relatively drug-impermeable film soluble in body fluids and thence rolling said coated film about itself in spiral or jeliyroli fashion.
  • the outermost extremities of the film gradually erode at a predetermined rate in body fluids thus exposing coextensive extremities of the drug coating, also soluble in body fluids, and drug is released to the tissues of the body.
  • Suitable design of the drug coating along the spiral e.g., of varying thickness, etc. provides for the aforesaid release patterns as the device disintegrates.
  • PATENTEDDEC nan 35251214 INVENTOR Takeru Higuchi Attorney nnuc-nnuvnav DEVICE BACKGROUND OF THE INVENTION
  • This invention relates to a device for delivering drugs to patients according to a programmed schedule and, more especially, to a device which can deliver drugs according to any desired program of release which may be therapeutically desired.
  • one feature resides in the application of a drug coating of varying or uniform thickness to a relatively impermeable film soluble in body fluids.
  • the coated film is spirally wound or rolled about itself in jellyroll fashion.
  • the film gradually erodes or dissolves at a predetennined rate in body fluids thus exposing the drug coating.
  • FIG. 1 is a side view of the coated substrate precursor structure of a drug-delivery device of this invention
  • FIG. la is a top view of a drug-delivery device of this invention, formed from the structure of FIG. 1;
  • FIG. lb is a side view of the structure of FIG. la;
  • FIG. 2 is a side view of a coated substrate precursor structure of another drug-delivery device of this invention.
  • FIG. 2a is a top view of another drug-delivery device of this invention, formed from the structure of FIG. 2;
  • FIG. 2b is a top view of another drug-delivery device of this invention, also formed from the structure of FIG. 2;
  • FIG. 20 is a side view of the structures of both FIG. 2a and FIG. 2b;
  • FIG. 3 is a side view of a coated substrate precursor structure of yet another drug-delivery device of this invention.
  • FIG. 3a is a top view of yet another drug-delivery device of this invention, formed from the structure of FIG. 3;
  • FIG. 3b is a side view of the structure of FIG. 3a;
  • FIG. 4 is a side view of a coated substrate precursor structure of still another drug-delivery device of this invention.
  • FIG. 4a is a top view of still another drug-delivery device of this invention, formed from the structure of FIG. 4;
  • FIG. 4b is a side view of the structure of FIG. 4a;
  • This invention has for its essence an assemblage of relatively impermeable film separating slowly soluble, medicament-containing matrix composition.
  • a relatively impermeable film 10 is shown which dissolves at a slow predetermined rate in body fluids.
  • the film 10 is coated with a medicament Ill containing matrix composition 12 of constant thickness, which matrix is soluble in body fluids (FIG. I).
  • the coated film is next spirally wound or rolled about itself in jellyroll" fashion to provide the drug-delivery device 13 of FIGS. Ia and lb.
  • the drug-delivery device of this invention is either physically inserted or surgically implanted in the body or is administered via the gastrointestinal tract.
  • the drug matrix layer becomes exposed and it too erodes, thus releasing the drug to the tissues of the body.
  • the matrix layer is thin, relatively small amounts of medication are released per amount of film eroded.
  • the matrix layer is thick the amount of medicament released will be enhanced.
  • a drug dosage unit which can exhibit a constant slow rate of release of drug.
  • FIG. 2 a relatively impenneable film I0 is also shown which dissolves very slowly in body fluids.
  • the said film I0 is coated with a medicament I1 containing matrix composition 12 of uniformly varying thickness, namely, the drug or matrix layer is spread thin at a proximal end of the surface of the film but uniformly progressively thicker across to the distal end of the surface of the film.
  • the drug-delivery device of this invention may be comprised of a drug-matrix layer such as to program any desired time release profile, and two other of such forms are illustrated in FIGS. 3, 3a, 3b, 4, 4a and 4b, with the FIGS. 3 depicting a unit which provides a pulsing release pattern and the FIGS. 41 a unit which provides a sinusoidal release pattern.
  • the drugdelivery device of the invention is also advantageously capped at either end with a material 14 slowly soluble in body fluids so as to prevent even the slightest amount of drug from prematurely exuding out of said ends (see FIG. 6).
  • the resulting device In many instances, it is desirable to provide for release of the drug immediately upon administration of the device. This can be achieved by coating the preformed device, as illustrated in any of FIGS. 10, 2a, 2b, 3a, da and 5, with a layer of the matrix 112 containing drug 11.
  • film It can be coated with medicament 11 containing matrix composition 12 on both face surfaces thereof. Upon rolling this coated film about itself, the resulting device will bear a drug-containing coating on its exterior surface (FIG. 7a). In either event, the resulting device initially will release drug by dissolution of the exteriorly exposed coating of the matrix. Thereafter, the film will dissolve, eventually releasing drug disposed within the interior of the spirally wound device.
  • the film or carrier materials 10 are flexible and relatively resistant to erosion in body fluids to provide for medicating action over a prolonged period of time and are preferably polymeric in nature.
  • Exemplary materials include polymers of the following three general classes: (1 those which slowly dissolve in body fluids, for example, gelatin, glycerinated gelatin, formalin treated gelatin, collagen, polyvinylalcohol, and the like; (2) those which hydrolyze in body fluids, for example, the polymeric, essentially linear, dibasic acid anhydrides of the formula:
  • polyanhydride polymers of sebacic and azelaic acids especially the polyanhydride polymers of sebacic and azelaic acids, polyhydroxyacetic acid such as described in U.S. Pat. Nos. 2,668,162 and 2,676,945, and polysulfite polymers; and (3) polymers cleaved by enzymes present in body fluids. for example, chitin, which is enzymatically cleaved by lysozyme.
  • the polyanhydride polymers of theabove type (2) can be conveniently prepared by condensing the respective dibasic acids in the presence of SOCl,, benzene and ethyl acetate.
  • the film or carrier material should be relatively impermeable to passage of the drug by difiusion or leaching. Otherwise, the rate of release of the drug will depend, at least in part, upon diffusion through the film rather than upon erosion of the film and matrix. Selection of appropriate membrane materials will be dependent on the particular drug to be used, and those skilled in the art can readily make the appropriate choices.
  • Matrix materials used in fabricating the drug coating of constant or varying thickness are soluble in body fluids.
  • the drug matrix substance must erode faster than the film such that, when physically inserted or implanted in the body or administered via the gastrointestinal tract, the film first erodes or dissolves in body fluids thus exposing the drug coating which thence itself erodes or dissolves and hence provides a slow rate of release of drug, albeit the erosion or dissolution is more rapid than that of the film material.
  • erosion or dissolution of the film is the rate controlling step for drug administration; for once the film erodes at its predetennined rate, the drug is released relatively rapidly by dissolution of the matrix.
  • Exemplary matrix materials include polyvinylpyrrolidone, water soluble starch, gum acacia, gum tragacanth, or the like, or even those film materials hereinbefore delineated, so long as the requirement is observed that the selected drug matrix substance must erode or dissolve faster than the selected film.
  • Drug used to treat the body can be incorporated in the drug layer of the drug-delivery device of this invention.
  • Drug is used herein in its broadest sense as including any composition or substance that will produce a pharmacologic response.
  • Suitable drugs for use in therapy with the device of the invention include without limitation:
  • Protein drugs such as insulin
  • Desensitizing agents such as ragweed pollen antigens, hay fever pollen antigens, dust antigen and milk antigen;
  • Vaccines such as smallpox, yellow fever, distemper, hog cholera, fowl pox, antivenom, scarlet fever, dyptheria toxoid, tetanus toxoid, pigeon pox, whooping cough, influenzae, rabies, mumps, measles, poliomyelitis, Newcastle disease, etc.;
  • Antiinfectives such as antibiotics, including penicillin, tetracycline, chlortetracycline bacitracin, nystatin, streptomycin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, and erythromycin; sulfonamides, including sulfacetamide, sulfamethizole, sulfamethazine, sulfadiazine, sulfamerazine, and sulfisoxazole; anti-virals including idoxuridine; and other antiinfectives including nitrofurazone and sodium propionate;
  • Antiallergenics such as antazoline, methapyrilene, chlorpheniramine, pyrilamine and prophenpyridamine;
  • Antiallergenics such as hydrocortisone, cortisone, hydrocortisone acetate, dexamethasone, dexamethasone 2lphosphate, fluocinolone, triamcinolone, medrysone, prednisolone, prednisolone 2l-phosphate, and prednisolone acetate;
  • Decongestants such as phenylcphrine, naphazoline, and tetrahydrazoline;
  • Miotics and anticholinesterases such as pilocarpine, eserine salicylate, carbachol, diisopropyl fluorophosphate, phospholine iodide, and demecarium bromide;
  • Sedatives and Hypnotics such as pentabarbital sodium, phenobarbital, secobarbital sodium, codeine, (abromoisovaleryl) urea, carbromal;
  • Psychic Energizers such as 3-(2-aminopropyl) indole acetate and 3-(2-aminobutyl) indole acetate;
  • Tranquilizers such as reserpine, chlorpromayline, and thiopropazate;
  • Androgenic steroids such as methyltestosterone and fluorymesterone
  • Estrogens such as estrone, l7 B-estradiol, ethinyl estradiol, and diethyl stilbesterol;
  • Progestational agents such as progesterone, megestrol, melengestrol, chlormadinonc, ethisterone, norethynodrel, l9- nor-progesterone, norethindrone, medroxyprogesterone and 17 B-hydroxy-progesterone;
  • Humoral agents such as the prostaglandins, for example PGE PGE and PGF l8.
  • Antipyretics such as aspirin, sodium salicylate, and salicylamide;
  • Antispasmodics such as atropine, mcthantheline, papaverine, and methscopolamine bromide;
  • Antimalarials such as the 4-aminoquinolines, 8- aminoquinolines, chloroquine, and pyrimethamine;
  • Antihistamines such as diphenhydramine, dimenhydrinate, tripelennamine, perphenazine, and chlorophenazine;
  • Cardioactive agents such as dibenzhydroflumethiazide, flumethiazide, chlorothiazide, and aminotrate;
  • Nutritional agents such as vitamins, essential amino acids and essential fats.
  • Drugs can be in various forms, such as uncharged molecules, components of molecular complexes, or nonirritating, pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulfate, phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, etc.
  • pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulfate, phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, etc.
  • salts of metals, amines, or organic cations e.g., quaternary ammonium
  • simple derivatives of the drugs such as ethers, esters, amides, etc.
  • body pH, enzymes, etc. can be employed.
  • the amount of drug incorporated in the drug-delivery device varies widely depending on the particular drug, the desired therapeutic elTect, and the time span for which it takes the film barrier and matrix material to erode or dissolve. Since a variety of devices in a variety of sizes and shapes are intended to provide complete dosage regimes for therapy for a variety of maladies, there is no critical upper limit on the amount of drug incorporated in the device. The lower limit too will depend on the activity of the drug and the time span of its release from the device. Thus it is not practical to define a range for the therapeutically effective amount of drug to be released by the device.
  • the drug is mixed with the matrix material either at ambient or elevated temperatures to form a settable mixture.
  • the settable mixture whether a dispersion or true solution, is then simply spread on the film substrate in constant or varying thicknesses (see the FIGS. of the drawing) and allowed to set, for example, by drying or hardening.
  • the coated film is next spirally wound or rolled about itself in jellyroll to provide the subject device.
  • the drug release profile of the device is determined. in most instances, a matrix of uniform drug concentration is applied over one entire surface of the film, at a constant or varying thickness.
  • the matrix can be printed onto the film in various patterns, providing different rates of drug release.
  • different portions of the film can be coated with matrix portions having different drug concentration. in each of these ways, the rate of release of drug from the device can be controlled and a wide variety of release patterns obtained.
  • the drug-delivery device can be fabricated in any convenient shape for either physical insertion or implantation in the body or for administration via the gastrointestinal tract. Dimensions of the device can thus vary widely and are not of controlling importance.
  • the lower limit of the size of the device is governed by the amount of the particular drug to be supplied to the body to elicit the desired pharmacologic response, as well as by the form the dosage unit takes, for example, implantate, suppository, peroral pellet, oral bolus, vaginal pessory, buccal or sublingual lozenge, ocular insert (e.g. as described in US. Pat. No. 3,416,530), the like.
  • the upper limit on the size of the device Likewise with respect to the upper limit on the size of the device.
  • any predetermined time release profile can be embodied in devices other than drug-delivery devices, namely, in any device where it is desired to provide for the prolonged release of any active ingredient according to any desired release pattern.
  • a drug-delivery device for prolongedly delivering drugs according to any predetermined time release profile comprised of a spirally rolled substrate, said substrate being comprised of a relatively drug impermeable, flexible film erodible in body fluids and being coated with a drug-containing matrix composition, which matrix itself is erodible in body fluids.
  • the drug-delivery device as defined by claim 1 bearing an external coating of said drug-containing matrix composition.
  • a device for prolongedly delivering active ingredient to a given fluid environment according to any predetermined time release profile comprised of a spirally rolled substrate said substrate being comprised of a relatively active ingredient impermeable, flexible film erodible in a given fluid environment, said fllm being coated with an active ingredient containing matrix composition, which matrix itself is erodible in said given fluid environment.

Abstract

A drug-delivery device for prolongedly delivering drugs to patients according to any predetermined time release profile, e.g., increasing, decreasing, constant, pulsing, sinusoidal, and like patterns of release, is fabricated by applying a drug coating of varying or uniform thickness to a relatively drugimpermeable film soluble in body fluids and thence rolling said coated film about itself in spiral or ''''jellyroll'''' fashion. Upon administration to the body, the outermost extremities of the film gradually erode at a predetermined rate in body fluids thus exposing coextensive extremities of the drug coating, also soluble in body fluids, and drug is released to the tissues of the body. Suitable design of the drug coating along the spiral, e.g., of varying thickness, etc. provides for the aforesaid release patterns as the device disintegrates.

Description

United States Patent 3,184,386 5/1965 Stephenson 3,416,530 12/1968 Ness ABSTRACT: A drug-delivery device for prolongedly delivering drugs to patients according to any predetermined time release profile, e.g., increasing, decreasing, constant, pulsing, sinusoidal, and like patterns of release, is fabricated by applying a drug coating of varying or uniform thickness to a relatively drug-impermeable film soluble in body fluids and thence rolling said coated film about itself in spiral or jeliyroli fashion. Upon administration to the body, the outermost extremities of the film gradually erode at a predetermined rate in body fluids thus exposing coextensive extremities of the drug coating, also soluble in body fluids, and drug is released to the tissues of the body. Suitable design of the drug coating along the spiral, e.g., of varying thickness, etc. provides for the aforesaid release patterns as the device disintegrates.
PATENTEDDEC nan 35251214 INVENTOR. Takeru Higuchi Attorney nnuc-nnuvnav DEVICE BACKGROUND OF THE INVENTION This invention relates to a device for delivering drugs to patients according to a programmed schedule and, more especially, to a device which can deliver drugs according to any desired program of release which may be therapeutically desired.
In the pharmaceutical field, most prolonged or sustained action medicators have had as their objective to release medication at a constant rate. However, many programs of therapy require that the quantity of medication administered vary with time. For example, in antibiotic therapy, it is common to administer a large initial dose of drug followed by smaller doses. Conversely, in desensitizing against allergens, therapeutic regimes often call for dose of the allergen to progressively increase over the time of treatment. More complex regimes, in which the dose of medication varies through periodic high and low points, are also known. In general, these therapeutic programs are practiced by periodically administering different amounts of medication in separate dosage forms. Such practice requires frequent acts by the patient or trained attendant and departures from the therapeutic program often occur. Thus, a need exists for a drug-delivery device that can provide any desired time profile for drug administration.
SUMMARY OF THE INVENTION Accordingly, it is a primary object of this invention to pro vide a device for delivering drugs to patients according to any predetermined time release profile.
In attaining the objects of this invention, one feature resides in the application of a drug coating of varying or uniform thickness to a relatively impermeable film soluble in body fluids. To provide the drug-delivery unit, the coated film is spirally wound or rolled about itself in jellyroll fashion. When the device is physically inserted or implanted in the body or administered via the gastrointestinal tract, the film gradually erodes or dissolves at a predetennined rate in body fluids thus exposing the drug coating. By suitable design of the film and of the drug coating, which itself dissolves in body fluids, one can obtain any desired release pattern including increasing, decreasing, pulsing, constant, sinusoidal, etc.
Other objects, features and advantages of this invention will become more apparent from the following description when taken in conjunction with the accompanying drawings, and wherein like reference numerals are used to indicate like or equivalent parts.
BRIEF DESCRIPTION OF THE DRAWINGS In the drawings:
FIG. 1 is a side view of the coated substrate precursor structure of a drug-delivery device of this invention;
FIG. la is a top view of a drug-delivery device of this invention, formed from the structure of FIG. 1;
FIG. lb is a side view of the structure of FIG. la;
FIG. 2 is a side view of a coated substrate precursor structure of another drug-delivery device of this invention;
FIG. 2a is a top view of another drug-delivery device of this invention, formed from the structure of FIG. 2;
FIG. 2b is a top view of another drug-delivery device of this invention, also formed from the structure of FIG. 2;
FIG. 20 is a side view of the structures of both FIG. 2a and FIG. 2b;
FIG. 3 is a side view of a coated substrate precursor structure of yet another drug-delivery device of this invention;
FIG. 3a is a top view of yet another drug-delivery device of this invention, formed from the structure of FIG. 3;
FIG. 3b is a side view of the structure of FIG. 3a;
FIG. 4 is a side view of a coated substrate precursor structure of still another drug-delivery device of this invention;
FIG. 4a is a top view of still another drug-delivery device of this invention, formed from the structure of FIG. 4;
FIG. 4b is a side view of the structure of FIG. 4a;
DETAILED DESCRIPTION OF THE INVENTION This invention has for its essence an assemblage of relatively impermeable film separating slowly soluble, medicament-containing matrix composition. Referring particularly to FIGS. I and la, a relatively impermeable film 10 is shown which dissolves at a slow predetermined rate in body fluids. The film 10 is coated with a medicament Ill containing matrix composition 12 of constant thickness, which matrix is soluble in body fluids (FIG. I).
The coated film is next spirally wound or rolled about itself in jellyroll" fashion to provide the drug-delivery device 13 of FIGS. Ia and lb.
To use the drug-delivery device of this invention, it is either physically inserted or surgically implanted in the body or is administered via the gastrointestinal tract. As the film is eroded away by the action of either gastrointestinal tissue or other body fluids, the drug matrix layer becomes exposed and it too erodes, thus releasing the drug to the tissues of the body. When the matrix layer is thin, relatively small amounts of medication are released per amount of film eroded. Conversely, if the matrix layer is thick the amount of medicament released will be enhanced. By adjusting the thickness of the matrix or the concentration of drug therein, any desired time release profile can be programmed.
By use of the drug-delivery device of FIGS. la and lb which is comprised of a drug-matrix coating of constant thickness, there is provided a drug dosage unit which can exhibit a constant slow rate of release of drug.
In FIG. 2 a relatively impenneable film I0 is also shown which dissolves very slowly in body fluids. However, in this embodiment the said film I0 is coated with a medicament I1 containing matrix composition 12 of uniformly varying thickness, namely, the drug or matrix layer is spread thin at a proximal end of the surface of the film but uniformly progressively thicker across to the distal end of the surface of the film.
It will thus be appreciated that, depending upon from which end the assemblage is wound about itself, there can be conveniently prepared drug-delivery devices which will provide constantly decreasing slow rate of release of drug (FIG. 2a) or constantly increasing slow rate of release of drug (FIG. 2b). In either event such devices would be identical in side plan view (FIG. 2c).
As described and illustrated above, the drug-delivery device of this invention may be comprised of a drug-matrix layer such as to program any desired time release profile, and two other of such forms are illustrated in FIGS. 3, 3a, 3b, 4, 4a and 4b, with the FIGS. 3 depicting a unit which provides a pulsing release pattern and the FIGS. 41 a unit which provides a sinusoidal release pattern.
Moreover, even though in the FIGS. of the drawing cylindrical structures are shown, it is apparent that flattened (FIG. 5) or other configurations can be easily provided. The drugdelivery device of the invention is also advantageously capped at either end with a material 14 slowly soluble in body fluids so as to prevent even the slightest amount of drug from prematurely exuding out of said ends (see FIG. 6).
In many instances, it is desirable to provide for release of the drug immediately upon administration of the device. This can be achieved by coating the preformed device, as illustrated in any of FIGS. 10, 2a, 2b, 3a, da and 5, with a layer of the matrix 112 containing drug 11. Alternatively, as illustrated in FIG. '7, film It) can be coated with medicament 11 containing matrix composition 12 on both face surfaces thereof. Upon rolling this coated film about itself, the resulting device will bear a drug-containing coating on its exterior surface (FIG. 7a). In either event, the resulting device initially will release drug by dissolution of the exteriorly exposed coating of the matrix. Thereafter, the film will dissolve, eventually releasing drug disposed within the interior of the spirally wound device.
The film or carrier materials 10 are flexible and relatively resistant to erosion in body fluids to provide for medicating action over a prolonged period of time and are preferably polymeric in nature. Exemplary materials include polymers of the following three general classes: (1 those which slowly dissolve in body fluids, for example, gelatin, glycerinated gelatin, formalin treated gelatin, collagen, polyvinylalcohol, and the like; (2) those which hydrolyze in body fluids, for example, the polymeric, essentially linear, dibasic acid anhydrides of the formula:
especially the polyanhydride polymers of sebacic and azelaic acids, polyhydroxyacetic acid such as described in U.S. Pat. Nos. 2,668,162 and 2,676,945, and polysulfite polymers; and (3) polymers cleaved by enzymes present in body fluids. for example, chitin, which is enzymatically cleaved by lysozyme.
The polyanhydride polymers of theabove type (2) can be conveniently prepared by condensing the respective dibasic acids in the presence of SOCl,, benzene and ethyl acetate.
The film or carrier material should be relatively impermeable to passage of the drug by difiusion or leaching. Otherwise, the rate of release of the drug will depend, at least in part, upon diffusion through the film rather than upon erosion of the film and matrix. Selection of appropriate membrane materials will be dependent on the particular drug to be used, and those skilled in the art can readily make the appropriate choices.
Matrix materials used in fabricating the drug coating of constant or varying thickness are soluble in body fluids. The drug matrix substance must erode faster than the film such that, when physically inserted or implanted in the body or administered via the gastrointestinal tract, the film first erodes or dissolves in body fluids thus exposing the drug coating which thence itself erodes or dissolves and hence provides a slow rate of release of drug, albeit the erosion or dissolution is more rapid than that of the film material. In this manner, erosion or dissolution of the film is the rate controlling step for drug administration; for once the film erodes at its predetennined rate, the drug is released relatively rapidly by dissolution of the matrix. Exemplary matrix materials include polyvinylpyrrolidone, water soluble starch, gum acacia, gum tragacanth, or the like, or even those film materials hereinbefore delineated, so long as the requirement is observed that the selected drug matrix substance must erode or dissolve faster than the selected film.
Any of the drugs used to treat the body can be incorporated in the drug layer of the drug-delivery device of this invention. Drug is used herein in its broadest sense as including any composition or substance that will produce a pharmacologic response.
Suitable drugs for use in therapy with the device of the invention include without limitation:
l. Protein drugs such as insulin;
2. Desensitizing agents such as ragweed pollen antigens, hay fever pollen antigens, dust antigen and milk antigen;
3. Vaccines such as smallpox, yellow fever, distemper, hog cholera, fowl pox, antivenom, scarlet fever, dyptheria toxoid, tetanus toxoid, pigeon pox, whooping cough, influenzae, rabies, mumps, measles, poliomyelitis, Newcastle disease, etc.;
4. Antiinfectives, such as antibiotics, including penicillin, tetracycline, chlortetracycline bacitracin, nystatin, streptomycin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, and erythromycin; sulfonamides, including sulfacetamide, sulfamethizole, sulfamethazine, sulfadiazine, sulfamerazine, and sulfisoxazole; anti-virals including idoxuridine; and other antiinfectives including nitrofurazone and sodium propionate;
5. Antiallergenics such as antazoline, methapyrilene, chlorpheniramine, pyrilamine and prophenpyridamine;
6. Antiallergenics such as hydrocortisone, cortisone, hydrocortisone acetate, dexamethasone, dexamethasone 2lphosphate, fluocinolone, triamcinolone, medrysone, prednisolone, prednisolone 2l-phosphate, and prednisolone acetate;
7. Decongestants such as phenylcphrine, naphazoline, and tetrahydrazoline;
8. Miotics and anticholinesterases such as pilocarpine, eserine salicylate, carbachol, diisopropyl fluorophosphate, phospholine iodide, and demecarium bromide;
such as atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine, and hydroxyamphetamine;
l0. Sympathomimetics such as epinephrine;
l l. Sedatives and Hypnotics such as pentabarbital sodium, phenobarbital, secobarbital sodium, codeine, (abromoisovaleryl) urea, carbromal;
l2. Psychic Energizers such as 3-(2-aminopropyl) indole acetate and 3-(2-aminobutyl) indole acetate;
13. Tranquilizers such as reserpine, chlorpromayline, and thiopropazate;
l4. Androgenic steroids such as methyltestosterone and fluorymesterone;
15. Estrogens such as estrone, l7 B-estradiol, ethinyl estradiol, and diethyl stilbesterol;
l6. Progestational agents such as progesterone, megestrol, melengestrol, chlormadinonc, ethisterone, norethynodrel, l9- nor-progesterone, norethindrone, medroxyprogesterone and 17 B-hydroxy-progesterone;
l7. Humoral agents such as the prostaglandins, for example PGE PGE and PGF l8. Antipyretics such as aspirin, sodium salicylate, and salicylamide;
l9. Antispasmodics such as atropine, mcthantheline, papaverine, and methscopolamine bromide;
20. Antimalarials such as the 4-aminoquinolines, 8- aminoquinolines, chloroquine, and pyrimethamine;
21. Antihistamines such as diphenhydramine, dimenhydrinate, tripelennamine, perphenazine, and chlorophenazine;
22. Cardioactive agents such as dibenzhydroflumethiazide, flumethiazide, chlorothiazide, and aminotrate;
23. Nutritional agents such as vitamins, essential amino acids and essential fats.
Other drugs having the same or different physiological activity as those recited above can be employed in drug-delivery devices within the scope of the present invention.
Drugs can be in various forms, such as uncharged molecules, components of molecular complexes, or nonirritating, pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulfate, phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, etc. For acidic drugs, salts of metals, amines, or organic cations (e.g., quaternary ammonium) can be employed. Furthermore, simple derivatives of the drugs (such as ethers, esters, amides, etc.) which have desirable retention and release characteristics but which are easily hydrolyzed by body pH, enzymes, etc., can be employed.
The amount of drug incorporated in the drug-delivery device varies widely depending on the particular drug, the desired therapeutic elTect, and the time span for which it takes the film barrier and matrix material to erode or dissolve. Since a variety of devices in a variety of sizes and shapes are intended to provide complete dosage regimes for therapy for a variety of maladies, there is no critical upper limit on the amount of drug incorporated in the device. The lower limit too will depend on the activity of the drug and the time span of its release from the device. Thus it is not practical to define a range for the therapeutically effective amount of drug to be released by the device.
To prepare the drug-delivery device of the invention, the drug is mixed with the matrix material either at ambient or elevated temperatures to form a settable mixture. The settable mixture, whether a dispersion or true solution, is then simply spread on the film substrate in constant or varying thicknesses (see the FIGS. of the drawing) and allowed to set, for example, by drying or hardening. The coated film is next spirally wound or rolled about itself in jellyroll to provide the subject device.
In applying the drug-containing matrix to the film, the drug release profile of the device is determined. in most instances, a matrix of uniform drug concentration is applied over one entire surface of the film, at a constant or varying thickness. However, the matrix can be printed onto the film in various patterns, providing different rates of drug release. In addition, different portions of the film can be coated with matrix portions having different drug concentration. in each of these ways, the rate of release of drug from the device can be controlled and a wide variety of release patterns obtained.
The drug-delivery device can be fabricated in any convenient shape for either physical insertion or implantation in the body or for administration via the gastrointestinal tract. Dimensions of the device can thus vary widely and are not of controlling importance. The lower limit of the size of the device is governed by the amount of the particular drug to be supplied to the body to elicit the desired pharmacologic response, as well as by the form the dosage unit takes, for example, implantate, suppository, peroral pellet, oral bolus, vaginal pessory, buccal or sublingual lozenge, ocular insert (e.g. as described in US. Pat. No. 3,416,530), the like. Likewise with respect to the upper limit on the size of the device. One of the prime advantages of the dosage form of the invention over the capsule types of the prior art is that any inadvertent flaw in the protective film barrier will not suddenly release the entire drug content. Another advantage, if used as an implantate or the like, is the total disappearance of the film barrier when its function has been completed. Likewise as regards the drug matrix material.
It too will be appreciated that the principle of providing any predetermined time release profile can be embodied in devices other than drug-delivery devices, namely, in any device where it is desired to provide for the prolonged release of any active ingredient according to any desired release pattern.
While there have been shown and described and pointed out the fundamental novel features of the invention as applied to the preferred embodiment, those skilled in the art will appreciate that various modifications, changes, and omissions in the drug-delivery device illustrated and described can be made without departing from the spirit of the invention. It is the intention, therefore, to be limited only by the scope of the following claims.
What is claimed is:
l. A drug-delivery device for prolongedly delivering drugs according to any predetermined time release profile comprised of a spirally rolled substrate, said substrate being comprised of a relatively drug impermeable, flexible film erodible in body fluids and being coated with a drug-containing matrix composition, which matrix itself is erodible in body fluids.
2. The drug-delivery device as defined by claim 1, wherein the matrix composition is more rapidly erodible in body fluids than said film.
3. The drug-delivery device as defined by claim 1, wherein the drug is uniformly distributed throughout the matrix composition.
4. The drug-delivery device as defined by claim 3, wherein the drug coating is of constant thickness along the spiral.
5. The drugelivery device as defined by claim 3, wherein the drug coating is of varying thickness.
6. The drug-delivery device as defined by claim 3, wherein the thickness of the drug coating increases along the spiral.
7. The drug-delivery device as defined by claim 3, wherein the thickness of the drug coating decreases along the spiral.
8. The drug-delivery device as defined by claim 3, wherein the drug coating is of sinusoidal thickness along the spiral.
9. The drug-delivery device as defined by claim 5, wherein the film is comprised of a polymeric material which slowly dissolves in body fluids.
10. The drug-delivery device as defined by claim 3, wherein the film is comprised of polymeric material which hydrolyzes in body fluids.
11. The drugdelivery device as defined by claim 3, wherein the membrane is comprised of polymeric material which is cleaved by enzymes present in body fluids.
112. The drug-delivery device as defined by claim 1 bearing an external coating of said drug-containing matrix composition.
13. A device for prolongedly delivering active ingredient to a given fluid environment according to any predetermined time release profile comprised of a spirally rolled substrate said substrate being comprised of a relatively active ingredient impermeable, flexible film erodible in a given fluid environment, said fllm being coated with an active ingredient containing matrix composition, which matrix itself is erodible in said given fluid environment.
14. The method of prolongedly delivering drug to a patient according to any predetermined time release profile comprising administering to said patient the drug-delivery device as defined by claim ll.

Claims (14)

1. A drug-delivery device for prolongedly delivering drugs according to any predetermined time release profile comprised of a spirally rolled substrate, said substrate being comprised of a relatively drug impermeable, flexible film erodible in body fluids and being coated with a drug-containing matrix composition, which matrix itself is erodible in body fluids.
2. The drug-delivery device as defined by claim 1, wherein the matrix composition is more rapidly erodible in body fluids than said film.
3. The drug-delivery device as defined by claim 1, wherein the drug is uniformly distributed throughout the matrix composition.
4. The drug-delivery device as defined by claim 3, wherein the drug coating is of constant thickness along the spiral.
5. The drug-delivery device as defined by claim 3, wherein the drug coating is of varying thickness.
6. The drug-delivery device as defined by claim 3, wherein the thickness of the drug coating increases along the spiral.
7. The drug-delivery device as defined by claim 3, wherein the thickness of the drug coating decreases along the spiral.
8. The drug-delivery device as defined by claim 3, wherein the drug coating is of sinusoidal thickness along the spiral.
9. The drug-delivery device as defined by claim 5, wherein the film is comprised of a polymeric material which slowly dissolves in body fluids.
10. The drug-delivery device as defined by claim 3, wherein the film is comprised of polymeric material which hydrolyzes in body fluids.
11. The drug-delivery device as defined by claim 3, wherein the membrane is comprised of polymeric material which is cleaved by enzymes present in body fluids.
12. The drug-delivery device as defined by claim 1 bearing an external coating of said drug-containing matrix composition.
13. A device for prolongedly delivering active ingredient to a given fluid environment according to any predetermined time release profile comprised of a spirally rolled substrate said substrate being comprised of a relatively active ingredient impermeable, flexible film erodible in a given fluid environment, said film being coated with an active ingredient containing matrix composition, which matrix itself is erodible in said given fluid environment.
14. The method of prolongedly delivering drug to a patient according to any predetermined time release profile comprising administering to said patient the drug-delivery device as defined by claim 1.
US38237A 1970-05-18 1970-05-18 Drug-delivery device Expired - Lifetime US3625214A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3823770A 1970-05-18 1970-05-18

Publications (1)

Publication Number Publication Date
US3625214A true US3625214A (en) 1971-12-07

Family

ID=21898792

Family Applications (1)

Application Number Title Priority Date Filing Date
US38237A Expired - Lifetime US3625214A (en) 1970-05-18 1970-05-18 Drug-delivery device

Country Status (1)

Country Link
US (1) US3625214A (en)

Cited By (247)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826258A (en) * 1972-02-07 1974-07-30 S Abraham Gradual release medicine carrier
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3888975A (en) * 1972-12-27 1975-06-10 Alza Corp Erodible intrauterine device
US3892238A (en) * 1971-09-16 1975-07-01 Abbott Lab Drug supporting anchor
US3898986A (en) * 1972-12-27 1975-08-12 Alza Corp Biotransformable intrauterine device
US3926188A (en) * 1974-11-14 1975-12-16 Alza Corp Laminated drug dispenser
US3960150A (en) * 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3961628A (en) * 1974-04-10 1976-06-08 Alza Corporation Ocular drug dispensing system
US3971367A (en) * 1972-12-27 1976-07-27 Alza Corporation Intrauterine device having means for changing from uterine-retentive shape to nonuterine-retentive shape
US3981303A (en) * 1971-09-09 1976-09-21 Alza Corporation Bioerodible ocular device
US3986510A (en) * 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3993073A (en) * 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3993071A (en) * 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
DE2656387A1 (en) * 1975-12-15 1977-06-30 Hoffmann La Roche SOLID UNIVERSAL PHARMACEUTICAL DOSAGE FORM AS A DOSAGE FORM OF A DRUG, AND PROCESS AND SYSTEM FOR THEIR MANUFACTURING
NL7601017A (en) * 1976-02-02 1977-08-04 Minnesota Mining & Mfg Ballistically implantable projectile for animals - for controlled sustained release of biologically active materials on contact with animal body fluids
NL7601020A (en) * 1976-02-02 1977-08-04 Minnesota Mining & Mfg Ballistic animal inoculation projectile - with an antigen within a polymer body permitting antigen release
US4083741A (en) * 1975-12-15 1978-04-11 Hoffmann-La Roche, Inc. Novel dosage form
US4126503A (en) * 1975-12-15 1978-11-21 Hoffmann-La Roche Inc. Manufacture of pharmaceutical dosage forms
US4126502A (en) * 1975-12-15 1978-11-21 Hoffmann-La Roche Inc. Manufacture of pharmaceutical dosage forms
US4135514A (en) * 1974-12-23 1979-01-23 Alza Corporation Osmotic releasing system for administering ophthalmic drug to eye of animal
EP0010987A1 (en) * 1978-11-07 1980-05-14 Beecham Group Plc Device for oral administration to a ruminant animal
US4228149A (en) * 1977-06-09 1980-10-14 Beecham Group Limited Sustained release compositions
EP0021758A1 (en) * 1979-06-27 1981-01-07 Beecham Group Plc Veterinary preparations for ruminant animals
EP0064841A1 (en) * 1981-04-30 1982-11-17 Smith and Nephew Associated Companies p.l.c. Applicators for pharmaceutically active agents, their preparation and use
DE3124981A1 (en) * 1981-06-25 1983-01-13 Dr. Ruhland Nachfolger GmbH, 8425 Neustadt ACTIVE INGREDIENT COLLAGEN INSERT FOR INSERTION INTO BONES OR SOFT PARTS AND METHOD FOR THEIR PRODUCTION
US4439183A (en) * 1981-10-09 1984-03-27 Alza Corporation Parenteral agent dispensing equipment
US4521211A (en) * 1981-10-09 1985-06-04 Alza Corporation Parenteral agent dispensing equipment
US4548598A (en) * 1981-10-09 1985-10-22 Alza Corporation Parenteral agent dispensing equipment
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4698062A (en) * 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US4886870A (en) * 1984-05-21 1989-12-12 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4891225A (en) * 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4906474A (en) * 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4946929A (en) * 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
WO1991017745A1 (en) * 1990-05-23 1991-11-28 Southwest Research Institute Filament system for delivering a medicament and method
US5079006A (en) * 1987-07-15 1992-01-07 Aprex Corporation Pharmaceutical compositions containing a magnetically detectable material
US5114719A (en) * 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
US5236734A (en) * 1987-04-20 1993-08-17 Fuisz Technologies Ltd. Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix
US5238696A (en) * 1987-04-20 1993-08-24 Fuisz Technologies Ltd. Method of preparing a frozen comestible
WO1993021859A1 (en) * 1992-04-30 1993-11-11 Vincent Carmine Giampapa Tissue-specific implantable therapeutic agent delivery system
US5268110A (en) * 1991-05-17 1993-12-07 Fuisz Technologies Ltd. Oil removing method
US5279849A (en) * 1992-05-12 1994-01-18 Fuisz Technologies Ltd. Dispersible polydextrose, compositions containing same and method for the preparation thereof
US5286513A (en) * 1987-04-20 1994-02-15 Fuisz Technologies Ltd. Proteinaceous food product containing a melt spun oleaginous matrix
US5348758A (en) * 1992-10-20 1994-09-20 Fuisz Technologies Ltd. Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material
US5380473A (en) * 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
US5387431A (en) * 1991-10-25 1995-02-07 Fuisz Technologies Ltd. Saccharide-based matrix
US5407676A (en) * 1990-12-14 1995-04-18 Fuisz Technologies Ltd. Hydrophilic form of perfluoro compounds and a method of manufacture
US5427804A (en) * 1992-03-05 1995-06-27 Fuisz Technologies Ltd. Low-fat edible proteins with maltodextrins and low-saturate oils
US5445769A (en) * 1994-06-27 1995-08-29 Fuisz Technologies Ltd. Spinner head for flash flow processing
WO1995023598A1 (en) * 1994-03-04 1995-09-08 Trustees Of The Stevens Institute Of Technology Controlled release microporous membranes
US5456932A (en) * 1987-04-20 1995-10-10 Fuisz Technologies Ltd. Method of converting a feedstock to a shearform product and product thereof
US5464935A (en) * 1992-05-28 1995-11-07 Centocor, Inc. Peptide inhibitors of selectin binding
US5472731A (en) * 1987-04-20 1995-12-05 Fuisz Technologies Ltd. Protein based food product
US5501858A (en) * 1992-05-12 1996-03-26 Fuisz Technologies Ltd. Rapidly dispersable compositions containing polydextrose
US5516537A (en) * 1987-04-20 1996-05-14 Fuisz Technologies Ltd. Frozen comestibles
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5518551A (en) * 1993-09-10 1996-05-21 Fuisz Technologies Ltd. Spheroidal crystal sugar and method of making
US5520859A (en) * 1993-10-07 1996-05-28 Fuisz Technologies Ltd. Method for flash flow processing having feed rate control
EP0714912A2 (en) 1990-07-17 1996-06-05 The Board Of Regents Of The University Of Oklahoma GMP-140 derived lektin-like domain peptides and their ligands
US5545409A (en) * 1989-02-22 1996-08-13 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
US5549917A (en) * 1994-07-01 1996-08-27 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
US5556652A (en) * 1994-08-05 1996-09-17 Fuisz Technologies Ltd. Comestibles containing stabilized highly odorous flavor component delivery systems
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5576042A (en) * 1991-10-25 1996-11-19 Fuisz Technologies Ltd. High intensity particulate polysaccharide based liquids
US5587198A (en) * 1995-05-31 1996-12-24 Fuisz Technologies Ltd. Positive hydration method of preparing confectionery and product therefrom
US5593502A (en) * 1993-10-07 1997-01-14 Fuisz Technologies Ltd. Method of making crystalline sugar and products resulting therefrom
US5601835A (en) * 1987-04-29 1997-02-11 Massachusetts Institute Of Technology Polymeric device for controlled drug delivery to the CNS
US5602230A (en) * 1992-05-28 1997-02-11 Centocor, Inc. Peptide inhibitors of selectin binding
US5618785A (en) * 1993-11-22 1997-04-08 Centocor, Inc. Peptide inhibitors of selectin binding
US5622719A (en) * 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5624684A (en) * 1991-05-17 1997-04-29 Fuisz Technologies Ltd. Enzyme systems
US5651987A (en) * 1991-12-17 1997-07-29 Fuisz Technologies Ltd. Ulcer prevention and treatment composition
US5654273A (en) * 1994-09-22 1997-08-05 Children's Medical Center Corporation Synducin mediated modulation of tissue repair
US5654003A (en) * 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
US5695993A (en) * 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US5710123A (en) * 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
US5713852A (en) * 1995-06-07 1998-02-03 Alza Corporation Oral dosage and method for treating painful conditions of the oral cavity
US5728397A (en) * 1992-05-12 1998-03-17 Fuisz Technologies Ltd. Polydextrose product and process
US5753617A (en) * 1992-09-08 1998-05-19 Centocor, Inc. Peptide inhibitors of cellular adhesion
US5759539A (en) * 1995-06-06 1998-06-02 Georgia Research Foundation, Inc. Method for rapid enzymatic alcohol removal
EP0872234A2 (en) * 1997-04-16 1998-10-21 Röhm Gmbh Laminar medical formulation
US5843922A (en) * 1994-07-29 1998-12-01 Fuisz Technologies Ltd. Preparation of oligosaccharides and products therefrom
US5843884A (en) * 1995-11-15 1998-12-01 Oklahoma Medical Research Foundation C9 complement inhibitor
US5849900A (en) * 1992-09-29 1998-12-15 Max-Planck-Gesellschaft Zur Forderung Der Wissenschafter E.V. Inhibition of viruses by antisense oligomers capable of binding to polypurine rich tract of single-stranded RNA or RNA-DNA hybrids
US5851553A (en) * 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5853760A (en) * 1993-12-04 1998-12-29 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Device for the controlled release of active substances
US5859227A (en) * 1996-07-31 1999-01-12 Bearsden Bio, Inc. RNA sequences which interact with RNA-binding proteins
US5888982A (en) * 1996-04-01 1999-03-30 President And Fellows Of Harvard College Regulation of vascular smooth muscle cell heme oxygenase-1
US5895664A (en) * 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5898066A (en) * 1994-08-26 1999-04-27 Children's Medical Center Corporation Trophic factors for central nervous system regeneration
US5916876A (en) * 1992-09-08 1999-06-29 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
US5925333A (en) * 1995-11-15 1999-07-20 Massachusetts Institute Of Technology Methods for modulation of lipid uptake
US5962322A (en) * 1996-11-15 1999-10-05 Massachusetts Institute Of Technology Methods for modulation of cholesterol transport
US6001990A (en) * 1994-05-10 1999-12-14 The General Hospital Corporation Antisense inhibition of hepatitis C virus
US6004749A (en) * 1996-07-31 1999-12-21 Message Pharmaceuticals Method for identifying compounds affecting RNA/RNA binding protein interactions
US6020002A (en) * 1994-06-14 2000-02-01 Fuisz Technologies Ltd. Delivery of controlled-release system(s)
US6107029A (en) * 1996-07-31 2000-08-22 Message Pharmaceticals, Inc. Universal method for detecting interactions between RNA molecules and RNA binding proteins
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
JP2001501223A (en) * 1996-09-30 2001-01-30 アルザ コーポレイション Dosage form and drug administration
US6196993B1 (en) 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
US6200751B1 (en) 1996-11-08 2001-03-13 Oklahoma Medical Research Foundation Endothelial specific expression regulated by EPCR control elements
US6203813B1 (en) 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
WO2001022947A2 (en) * 1999-09-30 2001-04-05 Lts Lohmann Therapie-Systeme Ag Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same
US20010012847A1 (en) * 1996-11-12 2001-08-09 Lam Andrew C. Methods and devices for providing prolonged drug therapy
US6284729B1 (en) 1996-11-06 2001-09-04 Children's Medical Center Corporation Methods and reagents for regulating obesity
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6350859B1 (en) 1994-06-23 2002-02-26 Massachusetts Institute Of Technology Class BI and CI scavenger receptors
US6407236B1 (en) 1998-09-16 2002-06-18 Medco Research, Inc. Adenosine A3 receptor modulators
US6410508B1 (en) 1998-10-07 2002-06-25 Med College Georgia Res Inst Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US20030046718A1 (en) * 1999-06-28 2003-03-06 Massachusetts Institute Of Technology Screening of compounds for treatment of atherosclerosis and heart attack
US20030049784A1 (en) * 2001-08-30 2003-03-13 Mount Sinai School Of Medicine Of New York University Alternatively spliced circulating tissue factor
US20030157193A1 (en) * 2002-02-05 2003-08-21 Mcdonald William F. Antimicrobial polymer
FR2839645A1 (en) * 2002-05-15 2003-11-21 Backert Marie Elisabeth Cuine Multilayer system for oral administration of drug(s), especially with specific release profile, comprises polymeric film carrier coated by spreading with drug-containing matrix layer(s)
US20040077526A1 (en) * 1997-09-05 2004-04-22 Massachusetts Institute Of Technology SR-BI antagonist and use thereof as contraceptives and in the treatment of steroidal overproduction
US20040171073A1 (en) * 2002-10-08 2004-09-02 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
US20040210208A1 (en) * 2003-04-16 2004-10-21 Cook Incorporated Medical device with therapeutic agents
US20050031605A1 (en) * 2003-02-03 2005-02-10 Bunn Howard F. Compositions and methods of treating diabetes
US20050085844A1 (en) * 2002-12-24 2005-04-21 Ovion, Inc. Contraceptive device and delivery system
US20050107772A1 (en) * 2003-09-30 2005-05-19 Guohua Chen Osmotically driven active agent delivery device providing an ascending release profile
US20050124862A1 (en) * 2003-09-15 2005-06-09 Mousa Shaker A. Thyroid hormone analogs and methods of use
US20050129746A1 (en) * 2001-10-24 2005-06-16 Lee Brian C. Fluid-jet medicament delivery
US6921825B2 (en) 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
US20050223420A1 (en) * 2004-04-05 2005-10-06 Massachusetts Institute Of Technology Commonwealth Of Massachusetts Inducible heart attack animal model
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
US20060051391A1 (en) * 2004-09-09 2006-03-09 Dvoskin Victor O Device for the controlled administration of substances to be inserted in a body cavity
US20070009600A1 (en) * 1993-05-27 2007-01-11 Edgren David E Antidepressant dosage form
US7166568B1 (en) 1998-02-09 2007-01-23 Oklahoma Medical Research Foundation Compositions and methods to inhibit formation of the C5b-9 complex of complement
US7208467B2 (en) 2002-06-07 2007-04-24 Monty Krieger Lipid-altering compositions for the treatment of infertility
US20070196451A1 (en) * 2006-02-22 2007-08-23 Boston Scientific Scimed, Inc. Extendable rolled delivery system
US20070208074A1 (en) * 2006-01-24 2007-09-06 Bonni Azad M Methods and compositions for treating and preventing tumors
US20070282017A1 (en) * 2006-03-01 2007-12-06 Bonni Azad M Methods and compositions for treating and preventing neurologic disorders
US20080075663A1 (en) * 2006-06-20 2008-03-27 The J. David Gladstone Institutes Mouse Model of Chronic Heart Failure and Coronary Atherosclerosis Regression
US20080097380A1 (en) * 2006-09-21 2008-04-24 Li Kasey K Method and apparatus for creating variable stiffness and/or reduction of soft tissue
EP1920768A1 (en) * 2006-11-10 2008-05-14 Abbott GmbH & Co. KG Solid dosage form with a film containing an active substance, as well as its method of production
US20080124280A1 (en) * 2003-09-15 2008-05-29 Mousa Shaker A Thyroid Hormone Analogs and Methods of Use
US20080242608A1 (en) * 2006-06-02 2008-10-02 Azad Bonni Methods and compositions for treating and preventing neurologic disorders
US20090022806A1 (en) * 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
US20090104121A1 (en) * 2007-10-05 2009-04-23 Plaxgen, Inc Multi-subunit biological complexes for treatment of plaque-associated diseases
US20090175794A1 (en) * 2008-01-09 2009-07-09 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase ix
EP2133365A2 (en) 2006-12-27 2009-12-16 Emory University Compositions and methods for the treatment of infections and tumors
WO2010042759A2 (en) 2008-10-08 2010-04-15 Kyphia Pharmaceuticals Inc Gaba conjugates and methods of use thereof
US20100112600A1 (en) * 2006-07-13 2010-05-06 Azard Bonni Methods and compositions for modulating synapse formation
EP2194144A1 (en) 2004-11-16 2010-06-09 Trustees Of Boston University Roles for dual Endothelin-1/Angiotensin II receptor (DEAR) in hypertension and angiogenesis
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
US20100178246A1 (en) * 2008-12-05 2010-07-15 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting psma
US20100183509A1 (en) * 2008-01-09 2010-07-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
US20100209382A1 (en) * 2005-09-16 2010-08-19 Ordway Research Institute, Inc. Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
US20100255108A1 (en) * 2009-03-31 2010-10-07 Hung-Yun Lin Combination Treatment of Cancer With Cetuximab and Tetrac
US7824704B2 (en) 2003-05-02 2010-11-02 Surmodics, Inc. Controlled release bioactive agent delivery device
WO2010148007A2 (en) 2009-06-17 2010-12-23 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
US20110066141A1 (en) * 2009-09-11 2011-03-17 Cook Incorporated Implantable medical device having an anti-gastric distress agent
WO2011058164A1 (en) 2009-11-13 2011-05-19 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
WO2011061625A2 (en) 2009-11-19 2011-05-26 Solis Biodyne Compositions for increasing polypeptide stability and activity, and related methods
US20110142941A1 (en) * 2006-12-22 2011-06-16 Davis Paul J Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists, and Formulations and Uses Thereof
WO2011094430A2 (en) 2010-01-27 2011-08-04 Children's Medical Center Corporation Pro-angiogenic fragments of prominin-1 and uses thereof
WO2011116132A1 (en) 2010-03-16 2011-09-22 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
EP2380872A1 (en) 2004-06-15 2011-10-26 Polymedix, Inc. Polycationic compounds and uses thereof
EP2397155A1 (en) 2005-06-08 2011-12-21 Dana Farber Cancer Institute Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
EP2423331A2 (en) 2004-03-31 2012-02-29 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
EP2444038A2 (en) 2006-03-30 2012-04-25 Conceptus, Inc. Devices for deployment into a lumen
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US8211402B2 (en) 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
EP2476707A1 (en) 2003-11-14 2012-07-18 Children's Medical Center Corporation Self-cleaving ribozymes and uses thereof
WO2012109329A2 (en) 2011-02-08 2012-08-16 Children's Medical Center Corporation Methods for treatment of melanoma
US8246974B2 (en) 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012149326A1 (en) * 2011-04-29 2012-11-01 Massachusetts Institute Of Technology Layer processing for pharmaceuticals
WO2013054200A2 (en) 2011-10-10 2013-04-18 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
WO2013067451A2 (en) 2011-11-04 2013-05-10 Population Diagnostics Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
EP2662079A1 (en) 2012-05-10 2013-11-13 Ordway Research Institute, Inc. Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
WO2014043519A1 (en) 2012-09-14 2014-03-20 Population Diagnostics Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
US8821835B2 (en) 2000-11-16 2014-09-02 Microspherix Llc Flexible and/or elastic brachytherapy seed or strand
US20140309744A1 (en) * 2011-02-28 2014-10-16 Scimotana Pty Ltd Surgical implant and method
WO2015095767A1 (en) 2013-12-20 2015-06-25 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis and combinations thereof
WO2015105860A1 (en) 2014-01-07 2015-07-16 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
US9120837B2 (en) 2012-01-06 2015-09-01 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
WO2015149016A2 (en) 2014-03-28 2015-10-01 University Of Washington Through Its Center For Commercialization Breast and ovarian cancer vaccines
US9149547B2 (en) 2009-06-15 2015-10-06 Molecular Insight Pharmaceuticals, Inc. Process for production of heterodimers of glutamic acid
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
EP2963017A1 (en) 2002-03-11 2016-01-06 Molecular Insight Pharmaceuticals, Inc. Technetium-dipyridine complexes, and methods of use thereof
WO2016011386A1 (en) 2014-07-18 2016-01-21 University Of Washington Cancer vaccine compositions and methods of use thereof
WO2016054240A1 (en) 2014-09-30 2016-04-07 Sean Dalziel Fixed dose combinations for the treatment of viral diseases
US9308355B2 (en) 2012-06-01 2016-04-12 Surmodies, Inc. Apparatus and methods for coating medical devices
WO2016075578A1 (en) * 2014-11-16 2016-05-19 International Business Machines Corporation Helical coil delivery device for active agent
US9380813B2 (en) 2014-02-11 2016-07-05 Timothy McCullough Drug delivery system and method
US9393192B2 (en) 2002-07-29 2016-07-19 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone and risperidone
US9408986B2 (en) * 2014-02-11 2016-08-09 Timothy McCullough Methods and devices using cannabis vapors
WO2016149271A1 (en) 2015-03-19 2016-09-22 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US9682127B2 (en) 2005-02-03 2017-06-20 Intarcia Therapeutics, Inc. Osmotic delivery device comprising an insulinotropic peptide and uses thereof
EP3190108A1 (en) 2011-03-08 2017-07-12 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
US9707217B1 (en) 2017-02-03 2017-07-18 Osmotica Kereskedelmi Es Szolgaltato Kft Dose-dumping resistant controlled release dosage form
US9724293B2 (en) 2003-11-17 2017-08-08 Intarcia Therapeutics, Inc. Methods of manufacturing viscous liquid pharmaceutical formulations
WO2017192743A1 (en) 2016-05-04 2017-11-09 Abilita Bio, Inc. Methods and platform for preparing multispanning membrane proteins
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10059997B2 (en) 2010-08-02 2018-08-28 Population Bio, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
US10060934B2 (en) 2013-11-18 2018-08-28 Nanopharmaceuticals Llc Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
WO2018158632A2 (en) 2017-02-03 2018-09-07 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
US10086096B2 (en) 2013-01-14 2018-10-02 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US10149870B2 (en) 2012-02-29 2018-12-11 The General Hospital Corporation Compositions of microbiota and methods related thereto
USD835783S1 (en) 2016-06-02 2018-12-11 Intarcia Therapeutics, Inc. Implant placement guide
US10159714B2 (en) 2011-02-16 2018-12-25 Intarcia Therapeutics, Inc. Compositions, devices and methods of use thereof for the treatment of cancers
US10201616B2 (en) 2016-06-07 2019-02-12 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists
US10210306B2 (en) 2006-05-03 2019-02-19 Population Bio, Inc. Evaluating genetic disorders
US10213960B2 (en) 2014-05-20 2019-02-26 Massachusetts Institute Of Technology Plasticity induced bonding
US10231923B2 (en) 2009-09-28 2019-03-19 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US10233495B2 (en) 2012-09-27 2019-03-19 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US10407724B2 (en) 2012-02-09 2019-09-10 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US10501517B2 (en) 2016-05-16 2019-12-10 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US10527170B2 (en) 2006-08-09 2020-01-07 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
WO2020033700A1 (en) 2018-08-08 2020-02-13 Pml Screening, Llc Mathods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US10668116B2 (en) 2014-10-31 2020-06-02 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US10724096B2 (en) 2014-09-05 2020-07-28 Population Bio, Inc. Methods and compositions for inhibiting and treating neurological conditions
US10821240B2 (en) 2014-02-11 2020-11-03 Vapor Cartridge Technology Llc Methods and drug delivery devices using cannabis
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11034954B2 (en) 2018-06-29 2021-06-15 Wuhan Neurophth Biological Technology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US11352645B2 (en) 2018-08-20 2022-06-07 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating Leber's hereditary optic neuropathy
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US11357869B2 (en) 2019-12-09 2022-06-14 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy with NADH dehydrogenase proteins
WO2022195044A1 (en) * 2021-03-17 2022-09-22 Lts Lohmann Therapie-Systeme Ag Rolled oral thin films having a high level of active-ingredient loading
US11497249B2 (en) 2019-09-16 2022-11-15 Vapor Cartridge Technology Llc Drug delivery system with stackable substrates
WO2023280157A1 (en) 2021-07-05 2023-01-12 武汉纽福斯生物科技有限公司 Construction and use of anti-vegf antibody in-vivo expression system
US11583558B2 (en) 2017-08-30 2023-02-21 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
US11628466B2 (en) 2018-11-29 2023-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2099402A (en) * 1934-01-17 1937-11-16 Pratt Food Company Pill or tablet
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3184386A (en) * 1958-05-02 1965-05-18 Burroughs Wellcome Co Prolonged action medicinal tablets
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2099402A (en) * 1934-01-17 1937-11-16 Pratt Food Company Pill or tablet
US3184386A (en) * 1958-05-02 1965-05-18 Burroughs Wellcome Co Prolonged action medicinal tablets
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet

Cited By (447)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3993073A (en) * 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3981303A (en) * 1971-09-09 1976-09-21 Alza Corporation Bioerodible ocular device
US3993071A (en) * 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
US3986510A (en) * 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3960150A (en) * 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3892238A (en) * 1971-09-16 1975-07-01 Abbott Lab Drug supporting anchor
US3826258A (en) * 1972-02-07 1974-07-30 S Abraham Gradual release medicine carrier
US3971367A (en) * 1972-12-27 1976-07-27 Alza Corporation Intrauterine device having means for changing from uterine-retentive shape to nonuterine-retentive shape
US3898986A (en) * 1972-12-27 1975-08-12 Alza Corp Biotransformable intrauterine device
US3888975A (en) * 1972-12-27 1975-06-10 Alza Corp Erodible intrauterine device
US3961628A (en) * 1974-04-10 1976-06-08 Alza Corporation Ocular drug dispensing system
US3926188A (en) * 1974-11-14 1975-12-16 Alza Corp Laminated drug dispenser
US4142526A (en) * 1974-12-23 1979-03-06 Alza Corporation Osmotic releasing system with means for changing release therefrom
US4135514A (en) * 1974-12-23 1979-01-23 Alza Corporation Osmotic releasing system for administering ophthalmic drug to eye of animal
DE2656387A1 (en) * 1975-12-15 1977-06-30 Hoffmann La Roche SOLID UNIVERSAL PHARMACEUTICAL DOSAGE FORM AS A DOSAGE FORM OF A DRUG, AND PROCESS AND SYSTEM FOR THEIR MANUFACTURING
DK152172B (en) * 1975-12-15 1988-02-08 Hoffmann La Roche PROCEDURE FOR PREPARING A SOLID PHARMACEUTICAL UNIT DOSAGE FORM
US4083741A (en) * 1975-12-15 1978-04-11 Hoffmann-La Roche, Inc. Novel dosage form
US4126503A (en) * 1975-12-15 1978-11-21 Hoffmann-La Roche Inc. Manufacture of pharmaceutical dosage forms
US4126502A (en) * 1975-12-15 1978-11-21 Hoffmann-La Roche Inc. Manufacture of pharmaceutical dosage forms
NL7601017A (en) * 1976-02-02 1977-08-04 Minnesota Mining & Mfg Ballistically implantable projectile for animals - for controlled sustained release of biologically active materials on contact with animal body fluids
NL7601020A (en) * 1976-02-02 1977-08-04 Minnesota Mining & Mfg Ballistic animal inoculation projectile - with an antigen within a polymer body permitting antigen release
US4228149A (en) * 1977-06-09 1980-10-14 Beecham Group Limited Sustained release compositions
EP0010987A1 (en) * 1978-11-07 1980-05-14 Beecham Group Plc Device for oral administration to a ruminant animal
US4308250A (en) * 1978-11-07 1981-12-29 Beecham Group Limited Sustained drug release device
EP0021758A1 (en) * 1979-06-27 1981-01-07 Beecham Group Plc Veterinary preparations for ruminant animals
EP0064841A1 (en) * 1981-04-30 1982-11-17 Smith and Nephew Associated Companies p.l.c. Applicators for pharmaceutically active agents, their preparation and use
US4540408A (en) * 1981-04-30 1985-09-10 Smith And Nephew Associated Companies Limited Applicators for pharmacologically active agents, their preparation and use
DE3124981A1 (en) * 1981-06-25 1983-01-13 Dr. Ruhland Nachfolger GmbH, 8425 Neustadt ACTIVE INGREDIENT COLLAGEN INSERT FOR INSERTION INTO BONES OR SOFT PARTS AND METHOD FOR THEIR PRODUCTION
US4439183A (en) * 1981-10-09 1984-03-27 Alza Corporation Parenteral agent dispensing equipment
US4521211A (en) * 1981-10-09 1985-06-04 Alza Corporation Parenteral agent dispensing equipment
US4548598A (en) * 1981-10-09 1985-10-22 Alza Corporation Parenteral agent dispensing equipment
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4946929A (en) * 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4906474A (en) * 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4886870A (en) * 1984-05-21 1989-12-12 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4891225A (en) * 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4698062A (en) * 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
US5236734A (en) * 1987-04-20 1993-08-17 Fuisz Technologies Ltd. Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix
US5286513A (en) * 1987-04-20 1994-02-15 Fuisz Technologies Ltd. Proteinaceous food product containing a melt spun oleaginous matrix
US5472731A (en) * 1987-04-20 1995-12-05 Fuisz Technologies Ltd. Protein based food product
US5490993A (en) * 1987-04-20 1996-02-13 Fuisz Technologies Ltd. Method of preparing a proteinaceous food product containing a melt spun matrix and product thereof
US5503862A (en) * 1987-04-20 1996-04-02 Fuisz Technologies Ltd. Method of subjecting a protein-containing material to flash flow processing and product thereof
US5516537A (en) * 1987-04-20 1996-05-14 Fuisz Technologies Ltd. Frozen comestibles
US5238696A (en) * 1987-04-20 1993-08-24 Fuisz Technologies Ltd. Method of preparing a frozen comestible
US5456932A (en) * 1987-04-20 1995-10-10 Fuisz Technologies Ltd. Method of converting a feedstock to a shearform product and product thereof
US5374447A (en) * 1987-04-20 1994-12-20 Fuisz Technologies Ltd. Method of preparing a reduced-fat meat product
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5601835A (en) * 1987-04-29 1997-02-11 Massachusetts Institute Of Technology Polymeric device for controlled drug delivery to the CNS
US5114719A (en) * 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
US5079006A (en) * 1987-07-15 1992-01-07 Aprex Corporation Pharmaceutical compositions containing a magnetically detectable material
US5545409A (en) * 1989-02-22 1996-08-13 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
US5629009A (en) * 1989-02-22 1997-05-13 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
WO1991017745A1 (en) * 1990-05-23 1991-11-28 Southwest Research Institute Filament system for delivering a medicament and method
US5167962A (en) * 1990-05-23 1992-12-01 Southwest Research Institute Filament system for delivering a medicament and method
EP0714912A2 (en) 1990-07-17 1996-06-05 The Board Of Regents Of The University Of Oklahoma GMP-140 derived lektin-like domain peptides and their ligands
US5407676A (en) * 1990-12-14 1995-04-18 Fuisz Technologies Ltd. Hydrophilic form of perfluoro compounds and a method of manufacture
US6667036B2 (en) 1991-02-05 2003-12-23 The Board Of Regents Of The University Of Oklahoma Methods of treatment using antibodies to P-selectin glycoprotein ligand
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US20040132105A1 (en) * 1991-02-05 2004-07-08 Cummings Richard D. Methods of detecting disorders involving defective p-selectin glycoprotein ligand or defective p-selectin
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6506382B2 (en) 1991-02-05 2003-01-14 The Board Of Regents Of The University Of Oklahoma Method for inhibiting reperfusion injury using antibodies to P-selectin glycoprotein ligand
US5326568A (en) * 1991-05-03 1994-07-05 Giampapa Vincent C Method of tissue-specific delivery
US5268110A (en) * 1991-05-17 1993-12-07 Fuisz Technologies Ltd. Oil removing method
US6129926A (en) * 1991-05-17 2000-10-10 Fuisz Technologies Ltd. Flash flow processing of thermoplastic polymers and products made therefrom
US5624684A (en) * 1991-05-17 1997-04-29 Fuisz Technologies Ltd. Enzyme systems
US5429836A (en) * 1991-10-25 1995-07-04 Fuisz Technologies Ltd. Saccharide-based matrix
US5387431A (en) * 1991-10-25 1995-02-07 Fuisz Technologies Ltd. Saccharide-based matrix
US5597608A (en) * 1991-10-25 1997-01-28 Fuisz Technologies Ltd. Saccharide-based matrix incorporating maltodextrin and process for making
US5576042A (en) * 1991-10-25 1996-11-19 Fuisz Technologies Ltd. High intensity particulate polysaccharide based liquids
US5709876A (en) * 1991-10-25 1998-01-20 Fuisz Technologies Ltd. Saccharide-based matrix
US5651987A (en) * 1991-12-17 1997-07-29 Fuisz Technologies Ltd. Ulcer prevention and treatment composition
US5654003A (en) * 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
US5427804A (en) * 1992-03-05 1995-06-27 Fuisz Technologies Ltd. Low-fat edible proteins with maltodextrins and low-saturate oils
US5494677A (en) * 1992-04-30 1996-02-27 Giampapa; Vincent C. Tissue-specific implantable therapeutic agent delivery system
WO1993021859A1 (en) * 1992-04-30 1993-11-11 Vincent Carmine Giampapa Tissue-specific implantable therapeutic agent delivery system
US5501858A (en) * 1992-05-12 1996-03-26 Fuisz Technologies Ltd. Rapidly dispersable compositions containing polydextrose
US5279849A (en) * 1992-05-12 1994-01-18 Fuisz Technologies Ltd. Dispersible polydextrose, compositions containing same and method for the preparation thereof
US5728397A (en) * 1992-05-12 1998-03-17 Fuisz Technologies Ltd. Polydextrose product and process
US5602230A (en) * 1992-05-28 1997-02-11 Centocor, Inc. Peptide inhibitors of selectin binding
US5464935A (en) * 1992-05-28 1995-11-07 Centocor, Inc. Peptide inhibitors of selectin binding
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5753617A (en) * 1992-09-08 1998-05-19 Centocor, Inc. Peptide inhibitors of cellular adhesion
US5916876A (en) * 1992-09-08 1999-06-29 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
US5849900A (en) * 1992-09-29 1998-12-15 Max-Planck-Gesellschaft Zur Forderung Der Wissenschafter E.V. Inhibition of viruses by antisense oligomers capable of binding to polypurine rich tract of single-stranded RNA or RNA-DNA hybrids
US5348758A (en) * 1992-10-20 1994-09-20 Fuisz Technologies Ltd. Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material
US5380473A (en) * 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
US5710123A (en) * 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
US20070009600A1 (en) * 1993-05-27 2007-01-11 Edgren David E Antidepressant dosage form
US8084059B2 (en) 1993-05-27 2011-12-27 Alza Corporation Antidepressant dosage form
US5601076A (en) * 1993-09-10 1997-02-11 Fuisz Technologies Ltd. Spheroidal crystal sugar and method of making
US5895664A (en) * 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5827563A (en) * 1993-09-10 1998-10-27 Fuisz Technologies Ltd. Spheroidal crystal sugar
US5518551A (en) * 1993-09-10 1996-05-21 Fuisz Technologies Ltd. Spheroidal crystal sugar and method of making
US5851553A (en) * 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5622719A (en) * 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5866163A (en) * 1993-09-10 1999-02-02 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5871781A (en) * 1993-09-10 1999-02-16 Fuisz Technologies Ltd. Apparatus for making rapidly-dissolving dosage units
US5593502A (en) * 1993-10-07 1997-01-14 Fuisz Technologies Ltd. Method of making crystalline sugar and products resulting therefrom
US5597416A (en) * 1993-10-07 1997-01-28 Fuisz Technologies Ltd. Method of making crystalline sugar and products resulting therefrom
US5520859A (en) * 1993-10-07 1996-05-28 Fuisz Technologies Ltd. Method for flash flow processing having feed rate control
US5618785A (en) * 1993-11-22 1997-04-08 Centocor, Inc. Peptide inhibitors of selectin binding
US5853760A (en) * 1993-12-04 1998-12-29 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Device for the controlled release of active substances
US6110481A (en) * 1994-03-04 2000-08-29 Trustees Of The Stevens Institute Of Technology Controlled release device based on aqueous-organic partitioning in porous membranes
US5858385A (en) * 1994-03-04 1999-01-12 The Trustees Of The Stevens Institute Of Technology Controlled release device and method based on aqueous--organic partitioning in porous membranes
WO1995023598A1 (en) * 1994-03-04 1995-09-08 Trustees Of The Stevens Institute Of Technology Controlled release microporous membranes
US6001990A (en) * 1994-05-10 1999-12-14 The General Hospital Corporation Antisense inhibition of hepatitis C virus
US6020002A (en) * 1994-06-14 2000-02-01 Fuisz Technologies Ltd. Delivery of controlled-release system(s)
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5733577A (en) * 1994-06-14 1998-03-31 Fuisz Technologies Ltd. Delivery of controlled-release system (s)
US5851552A (en) * 1994-06-14 1998-12-22 Fuisz Technologies, Ltd. Delivery of controlled-release system(s)
US5853762A (en) * 1994-06-14 1998-12-29 Fuisz Technologies Ltd Delivery of controlled-release system(s)
US7078511B1 (en) 1994-06-23 2006-07-18 Massachusette Institute Of Technology Class BI and CI scavenger receptors
US6350859B1 (en) 1994-06-23 2002-02-26 Massachusetts Institute Of Technology Class BI and CI scavenger receptors
US5445769A (en) * 1994-06-27 1995-08-29 Fuisz Technologies Ltd. Spinner head for flash flow processing
US5824342A (en) * 1994-07-01 1998-10-20 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
US5582855A (en) * 1994-07-01 1996-12-10 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
US5549917A (en) * 1994-07-01 1996-08-27 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
US5843922A (en) * 1994-07-29 1998-12-01 Fuisz Technologies Ltd. Preparation of oligosaccharides and products therefrom
US5556652A (en) * 1994-08-05 1996-09-17 Fuisz Technologies Ltd. Comestibles containing stabilized highly odorous flavor component delivery systems
US5744180A (en) * 1994-08-05 1998-04-28 Fuisz Technologies Ltd. Comestibles containing stabilized highly odorous flavor component delivery systems
US5633027A (en) * 1994-08-05 1997-05-27 Fuisz Technologies Ltd. Confectioneries containing stabilized highly odorous flavor component delivery systems
US6399064B1 (en) 1994-08-12 2002-06-04 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US7063843B1 (en) 1994-08-12 2006-06-20 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US5695993A (en) * 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US5898066A (en) * 1994-08-26 1999-04-27 Children's Medical Center Corporation Trophic factors for central nervous system regeneration
US5654273A (en) * 1994-09-22 1997-08-05 Children's Medical Center Corporation Synducin mediated modulation of tissue repair
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US5756115A (en) * 1994-11-02 1998-05-26 The Population Coucil, Center For Biomedical Research Contraceptive method using a subdermally implantable device
US5587198A (en) * 1995-05-31 1996-12-24 Fuisz Technologies Ltd. Positive hydration method of preparing confectionery and product therefrom
US5804247A (en) * 1995-05-31 1998-09-08 Fuisz Technologies Ltd. Positive hydration method of preparing confectionary and product therefrom
US5759539A (en) * 1995-06-06 1998-06-02 Georgia Research Foundation, Inc. Method for rapid enzymatic alcohol removal
US5713852A (en) * 1995-06-07 1998-02-03 Alza Corporation Oral dosage and method for treating painful conditions of the oral cavity
US5925333A (en) * 1995-11-15 1999-07-20 Massachusetts Institute Of Technology Methods for modulation of lipid uptake
US5843884A (en) * 1995-11-15 1998-12-01 Oklahoma Medical Research Foundation C9 complement inhibitor
US5888982A (en) * 1996-04-01 1999-03-30 President And Fellows Of Harvard College Regulation of vascular smooth muscle cell heme oxygenase-1
US6107029A (en) * 1996-07-31 2000-08-22 Message Pharmaceticals, Inc. Universal method for detecting interactions between RNA molecules and RNA binding proteins
US5859227A (en) * 1996-07-31 1999-01-12 Bearsden Bio, Inc. RNA sequences which interact with RNA-binding proteins
US6004749A (en) * 1996-07-31 1999-12-21 Message Pharmaceuticals Method for identifying compounds affecting RNA/RNA binding protein interactions
JP4714313B2 (en) * 1996-09-30 2011-06-29 アルザ コーポレイション Dosage form and method of drug administration
JP2010195822A (en) * 1996-09-30 2010-09-09 Alza Corp Dosage form and method of administering drug
JP2001501223A (en) * 1996-09-30 2001-01-30 アルザ コーポレイション Dosage form and drug administration
US6284729B1 (en) 1996-11-06 2001-09-04 Children's Medical Center Corporation Methods and reagents for regulating obesity
US6200751B1 (en) 1996-11-08 2001-03-13 Oklahoma Medical Research Foundation Endothelial specific expression regulated by EPCR control elements
US20050025832A1 (en) * 1996-11-12 2005-02-03 Alza Corporation Methods and devices for providing prolonged drug therapy
US9000038B2 (en) 1996-11-12 2015-04-07 Alza Corporation Methods and devices for providing prolonged drug therapy
US8629179B2 (en) 1996-11-12 2014-01-14 Alza Corporation Methods and devices for providing prolonged drug therapy
US20050238709A1 (en) * 1996-11-12 2005-10-27 Alza Corporation Methods and devices for providing prolonged drug therapy
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US6930129B2 (en) 1996-11-12 2005-08-16 Alza Corporation Methods and devices for providing prolonged drug therapy
US9029416B2 (en) 1996-11-12 2015-05-12 Alza Corporation Methods and devices for providing prolonged drug therapy
US8163798B2 (en) 1996-11-12 2012-04-24 Alza Corporation Methods and devices for providing prolonged drug therapy
US20100093796A1 (en) * 1996-11-12 2010-04-15 Gupta Suneel K Methods and devices for providing prolonged drug therapy
US20010012847A1 (en) * 1996-11-12 2001-08-09 Lam Andrew C. Methods and devices for providing prolonged drug therapy
US9144549B2 (en) 1996-11-12 2015-09-29 Alza Corporation Methods and devices for providing prolonged drug therapy
US5962322A (en) * 1996-11-15 1999-10-05 Massachusetts Institute Of Technology Methods for modulation of cholesterol transport
US6203813B1 (en) 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
EP0872234A3 (en) * 1997-04-16 2001-01-24 Röhm Gmbh Laminar medical formulation
EP0872234A2 (en) * 1997-04-16 1998-10-21 Röhm Gmbh Laminar medical formulation
US6306428B1 (en) 1997-04-16 2001-10-23 Roehm Gmbh Chemische Fabrik Time-release laminar pharmaceutical composition
US20040077526A1 (en) * 1997-09-05 2004-04-22 Massachusetts Institute Of Technology SR-BI antagonist and use thereof as contraceptives and in the treatment of steroidal overproduction
US7166568B1 (en) 1998-02-09 2007-01-23 Oklahoma Medical Research Foundation Compositions and methods to inhibit formation of the C5b-9 complex of complement
US6196993B1 (en) 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6921825B2 (en) 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
US6407236B1 (en) 1998-09-16 2002-06-18 Medco Research, Inc. Adenosine A3 receptor modulators
US6410508B1 (en) 1998-10-07 2002-06-25 Med College Georgia Res Inst Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
US20030046718A1 (en) * 1999-06-28 2003-03-06 Massachusetts Institute Of Technology Screening of compounds for treatment of atherosclerosis and heart attack
US7361684B2 (en) 1999-06-28 2008-04-22 Massachusetts Institute Of Technology Screening of compounds for treatment of atherosclerosis and heart attack
US20080241216A1 (en) * 1999-09-30 2008-10-02 Lts Lohmann Therapie-Systeme Ag Preparation Containing Active and/or Auxiliary Substances, With Controllable Release of Said Substances, As Well As Its Use and Manufacture
WO2001022947A2 (en) * 1999-09-30 2001-04-05 Lts Lohmann Therapie-Systeme Ag Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same
WO2001022947A3 (en) * 1999-09-30 2001-10-11 Lohmann Therapie Syst Lts Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same
JP2003510270A (en) * 1999-09-30 2003-03-18 エルテーエス ローマン テラピー−ジステーメ アーゲー Formulations containing active and / or auxiliary substances and providing controlled release of said substances, and their use and manufacture
US10994058B2 (en) 2000-11-16 2021-05-04 Microspherix Llc Method for administering a flexible hormone rod
US9636402B2 (en) 2000-11-16 2017-05-02 Microspherix Llc Flexible and/or elastic brachytherapy seed or strand
US9636401B2 (en) 2000-11-16 2017-05-02 Microspherix Llc Flexible and/or elastic brachytherapy seed or strand
US8821835B2 (en) 2000-11-16 2014-09-02 Microspherix Llc Flexible and/or elastic brachytherapy seed or strand
US10493181B2 (en) 2000-11-16 2019-12-03 Microspherix Llc Flexible and/or elastic brachytherapy seed or strand
US7045350B2 (en) 2001-08-30 2006-05-16 Mount Sinai School Of Medicine Of New York University Alternatively spliced circulating tissue factor
US20030049784A1 (en) * 2001-08-30 2003-03-13 Mount Sinai School Of Medicine Of New York University Alternatively spliced circulating tissue factor
US20110204085A1 (en) * 2001-10-24 2011-08-25 Hewlett-Packard Development Company, L.P. Fluid-jet medicament delivery
US20050129746A1 (en) * 2001-10-24 2005-06-16 Lee Brian C. Fluid-jet medicament delivery
US20030157193A1 (en) * 2002-02-05 2003-08-21 Mcdonald William F. Antimicrobial polymer
EP2963017A1 (en) 2002-03-11 2016-01-06 Molecular Insight Pharmaceuticals, Inc. Technetium-dipyridine complexes, and methods of use thereof
WO2003097019A1 (en) * 2002-05-15 2003-11-27 Marie Elisabeth Cuine-Backert Multilamellar system for the administration of active agents by means of ingestion
FR2839645A1 (en) * 2002-05-15 2003-11-21 Backert Marie Elisabeth Cuine Multilayer system for oral administration of drug(s), especially with specific release profile, comprises polymeric film carrier coated by spreading with drug-containing matrix layer(s)
US20050175699A1 (en) * 2002-05-15 2005-08-11 Cuine-Backert Marie E. Multilamellar system for the administration of active agents by means of ingestion
US20040006129A1 (en) * 2002-05-16 2004-01-08 Massachusetts Institute Of Technology Prevention or treatment of abnormal lipoprotein, atherosclerosis and cholestasis
US7208467B2 (en) 2002-06-07 2007-04-24 Monty Krieger Lipid-altering compositions for the treatment of infertility
US9393192B2 (en) 2002-07-29 2016-07-19 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20040171073A1 (en) * 2002-10-08 2004-09-02 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
US20050085844A1 (en) * 2002-12-24 2005-04-21 Ovion, Inc. Contraceptive device and delivery system
US20050031605A1 (en) * 2003-02-03 2005-02-10 Bunn Howard F. Compositions and methods of treating diabetes
US20040210208A1 (en) * 2003-04-16 2004-10-21 Cook Incorporated Medical device with therapeutic agents
US20080051737A1 (en) * 2003-04-16 2008-02-28 Cook Incorporated Medical device with therapeutic agents
US7780647B2 (en) 2003-04-16 2010-08-24 Cook Incorporated Medical device with therapeutic agents
US7306580B2 (en) 2003-04-16 2007-12-11 Cook Incorporated Medical device with therapeutic agents
WO2004093962A1 (en) * 2003-04-16 2004-11-04 Cook Incorporated Medical device with therapeutic agents.
US7976862B2 (en) 2003-05-02 2011-07-12 Surmodics, Inc. Controlled release bioactive agent delivery device
US8021680B2 (en) 2003-05-02 2011-09-20 Surmodics, Inc. Controlled release bioactive agent delivery device
US8034369B2 (en) 2003-05-02 2011-10-11 Surmodics, Inc. Controlled release bioactive agent delivery device
US8246974B2 (en) 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
US7824704B2 (en) 2003-05-02 2010-11-02 Surmodics, Inc. Controlled release bioactive agent delivery device
US20080124280A1 (en) * 2003-09-15 2008-05-29 Mousa Shaker A Thyroid Hormone Analogs and Methods of Use
US8518451B2 (en) 2003-09-15 2013-08-27 Albany College of Pharmacy and Health Services Thyroid hormone analogs and methods of use
US8071134B2 (en) 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US9980933B2 (en) 2003-09-15 2018-05-29 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US20050124862A1 (en) * 2003-09-15 2005-06-09 Mousa Shaker A. Thyroid hormone analogs and methods of use
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US9750709B2 (en) 2003-09-15 2017-09-05 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US20100112079A1 (en) * 2003-09-15 2010-05-06 Ordway Research Institute, Inc. Thyroid Hormone Analogs and Methods of Use
EP2335694A1 (en) 2003-09-15 2011-06-22 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use.
US9579300B2 (en) 2003-09-15 2017-02-28 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US7785632B2 (en) 2003-09-15 2010-08-31 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US7241457B2 (en) * 2003-09-30 2007-07-10 Alza Corporation Osmotically driven active agent delivery device providing an ascending release profile
US20050107772A1 (en) * 2003-09-30 2005-05-19 Guohua Chen Osmotically driven active agent delivery device providing an ascending release profile
EP3279328A1 (en) 2003-11-14 2018-02-07 Children's Medical Center Corporation Self-cleaving ribozymes and uses thereof
EP2476707A1 (en) 2003-11-14 2012-07-18 Children's Medical Center Corporation Self-cleaving ribozymes and uses thereof
US9724293B2 (en) 2003-11-17 2017-08-08 Intarcia Therapeutics, Inc. Methods of manufacturing viscous liquid pharmaceutical formulations
EP2439285A1 (en) 2004-03-31 2012-04-11 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
EP2439284A1 (en) 2004-03-31 2012-04-11 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
EP2423331A2 (en) 2004-03-31 2012-02-29 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
EP3611273A1 (en) 2004-03-31 2020-02-19 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
EP2447375A2 (en) 2004-03-31 2012-05-02 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
US7514592B2 (en) 2004-04-05 2009-04-07 Massachusetts Institute Of Technology Inducible heart attack animal model
US20050223420A1 (en) * 2004-04-05 2005-10-06 Massachusetts Institute Of Technology Commonwealth Of Massachusetts Inducible heart attack animal model
EP2380872A1 (en) 2004-06-15 2011-10-26 Polymedix, Inc. Polycationic compounds and uses thereof
US20060051391A1 (en) * 2004-09-09 2006-03-09 Dvoskin Victor O Device for the controlled administration of substances to be inserted in a body cavity
EP2194144A1 (en) 2004-11-16 2010-06-09 Trustees Of Boston University Roles for dual Endothelin-1/Angiotensin II receptor (DEAR) in hypertension and angiogenesis
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US10363287B2 (en) 2005-02-03 2019-07-30 Intarcia Therapeutics, Inc. Method of manufacturing an osmotic delivery device
US9682127B2 (en) 2005-02-03 2017-06-20 Intarcia Therapeutics, Inc. Osmotic delivery device comprising an insulinotropic peptide and uses thereof
EP2397156A1 (en) 2005-06-08 2011-12-21 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1)pathway
EP2397155A1 (en) 2005-06-08 2011-12-21 Dana Farber Cancer Institute Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
EP3130350A1 (en) 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
EP4242655A2 (en) 2005-06-08 2023-09-13 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US9272049B2 (en) 2005-09-16 2016-03-01 Nanopharmaceuticals Llc Methods of stimulating fat mobilization using a polymer conjugated polyphenol
US20100209382A1 (en) * 2005-09-16 2010-08-19 Ordway Research Institute, Inc. Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use
US20070208074A1 (en) * 2006-01-24 2007-09-06 Bonni Azad M Methods and compositions for treating and preventing tumors
US20070196451A1 (en) * 2006-02-22 2007-08-23 Boston Scientific Scimed, Inc. Extendable rolled delivery system
WO2007097867A1 (en) * 2006-02-22 2007-08-30 Boston Scientific Scimed, Inc. Extendable rolled delivery system
US20070282017A1 (en) * 2006-03-01 2007-12-06 Bonni Azad M Methods and compositions for treating and preventing neurologic disorders
US7786090B2 (en) 2006-03-01 2010-08-31 President And Fellows Of Harvard College Methods and compositions for treating and preventing neurologic disorders
EP2444038A2 (en) 2006-03-30 2012-04-25 Conceptus, Inc. Devices for deployment into a lumen
US8707958B2 (en) 2006-03-30 2014-04-29 Bayer Essure Inc. Methods and devices for deployment into a lumen
US8235047B2 (en) 2006-03-30 2012-08-07 Conceptus, Inc. Methods and devices for deployment into a lumen
US10210306B2 (en) 2006-05-03 2019-02-19 Population Bio, Inc. Evaluating genetic disorders
US10529441B2 (en) 2006-05-03 2020-01-07 Population Bio, Inc. Evaluating genetic disorders
US10522240B2 (en) 2006-05-03 2019-12-31 Population Bio, Inc. Evaluating genetic disorders
US20080242608A1 (en) * 2006-06-02 2008-10-02 Azad Bonni Methods and compositions for treating and preventing neurologic disorders
US7960606B2 (en) 2006-06-20 2011-06-14 The J. David Gladstone Institutes Mouse model of chronic heart failure and coronary atherosclerosis regression
US20080075663A1 (en) * 2006-06-20 2008-03-27 The J. David Gladstone Institutes Mouse Model of Chronic Heart Failure and Coronary Atherosclerosis Regression
US20100112600A1 (en) * 2006-07-13 2010-05-06 Azard Bonni Methods and compositions for modulating synapse formation
US10527170B2 (en) 2006-08-09 2020-01-07 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
US20080097380A1 (en) * 2006-09-21 2008-04-24 Li Kasey K Method and apparatus for creating variable stiffness and/or reduction of soft tissue
US8673344B2 (en) * 2006-11-10 2014-03-18 AbbVie Deutschland GmbH & Co. KG Solid dosage form with a film containing an active substance, as well as its method of production
EP1920768A1 (en) * 2006-11-10 2008-05-14 Abbott GmbH & Co. KG Solid dosage form with a film containing an active substance, as well as its method of production
JP2014114309A (en) * 2006-11-10 2014-06-26 Abbott Gmbh & Kg Solid dosage form with film containing active substance, as well as its method of production
US20100119583A1 (en) * 2006-11-10 2010-05-13 Abbott Gmbh & Co. Kg Solid dosage form with a film containing an active substance, as well as its method of production
JP2010509295A (en) * 2006-11-10 2010-03-25 アボット ゲーエムベーハー ウント コンパニー カーゲー Solid dosage form having a film containing an active substance and method for producing the same
WO2008056001A1 (en) * 2006-11-10 2008-05-15 Abbott Gmbh & Co. Kg Solid dosage form with a film containing an active substance, as well as its method of production
US20090022806A1 (en) * 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
US20110142941A1 (en) * 2006-12-22 2011-06-16 Davis Paul J Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists, and Formulations and Uses Thereof
US9289395B2 (en) 2006-12-22 2016-03-22 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
EP2133365A2 (en) 2006-12-27 2009-12-16 Emory University Compositions and methods for the treatment of infections and tumors
EP3721903A1 (en) 2006-12-27 2020-10-14 Emory University Compositions and methods for the treatment of infections and tumors
EP3064220A2 (en) 2006-12-27 2016-09-07 Emory University Compositions and methods for the treatment of infections and tumors
US20090104121A1 (en) * 2007-10-05 2009-04-23 Plaxgen, Inc Multi-subunit biological complexes for treatment of plaque-associated diseases
US8932558B2 (en) 2007-10-05 2015-01-13 Plaxgen Inc Multi-subunit biological complexes for treatment of plaque-associated diseases
US8840865B2 (en) 2008-01-09 2014-09-23 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
US20100183509A1 (en) * 2008-01-09 2010-07-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
US20090175794A1 (en) * 2008-01-09 2009-07-09 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase ix
US8562945B2 (en) 2008-01-09 2013-10-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
US8877970B2 (en) 2008-01-09 2014-11-04 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase IX
US9433594B2 (en) 2008-01-09 2016-09-06 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
US8962799B2 (en) 2008-01-09 2015-02-24 Molecular Insight Pharmaceuticals, Inc. Technetium—and rhenium-bis(heteroaryl) complexes and methods of use thereof
US10441528B2 (en) 2008-02-13 2019-10-15 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20100113497A1 (en) * 2008-10-08 2010-05-06 Kyphia Pharmaceuticals, Inc. Gaba conjugates and methods of use thereof
WO2010042759A2 (en) 2008-10-08 2010-04-15 Kyphia Pharmaceuticals Inc Gaba conjugates and methods of use thereof
US10478412B2 (en) 2008-10-08 2019-11-19 Xgene Pharmaceutical Inc. GABA conjugates and methods of use thereof
EP3075722A1 (en) 2008-10-08 2016-10-05 Xgene Pharmaceutical Inc Gaba conjugates and methods of use thereof
US8268887B2 (en) 2008-10-08 2012-09-18 Feng Xu Drug conjugates and methods of use thereof
US9186341B2 (en) 2008-10-08 2015-11-17 Feng Xu GABA conjugates and methods of use thereof
US20100178246A1 (en) * 2008-12-05 2010-07-15 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting psma
US8211401B2 (en) 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA
EP2706057A1 (en) 2008-12-05 2014-03-12 Molecular Insight Pharmaceuticals, Inc. Bis(imidazolyl)compounds and radionuclide complexes
US8211402B2 (en) 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
WO2010075332A1 (en) 2008-12-23 2010-07-01 Charitable Leadership Foundation Small molecule ligands of the integrin rgd recognition site and methods of use
US20100255108A1 (en) * 2009-03-31 2010-10-07 Hung-Yun Lin Combination Treatment of Cancer With Cetuximab and Tetrac
US9180107B2 (en) 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
US9149547B2 (en) 2009-06-15 2015-10-06 Molecular Insight Pharmaceuticals, Inc. Process for production of heterodimers of glutamic acid
US9839614B2 (en) 2009-06-17 2017-12-12 Nanopharmaceuticals, Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20110052715A1 (en) * 2009-06-17 2011-03-03 Davis Paul J Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
WO2010148007A2 (en) 2009-06-17 2010-12-23 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof
US9220788B2 (en) 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20110066141A1 (en) * 2009-09-11 2011-03-17 Cook Incorporated Implantable medical device having an anti-gastric distress agent
US10869830B2 (en) 2009-09-28 2020-12-22 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US10231923B2 (en) 2009-09-28 2019-03-19 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
WO2011058164A1 (en) 2009-11-13 2011-05-19 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9816078B2 (en) 2009-11-19 2017-11-14 Solis Biodyne Oü Compositions for increasing polypeptide stability and activity, and related methods
EP3461889A1 (en) 2009-11-19 2019-04-03 Solis Biodyne Compositions for increasing polypeptide stability and activity, and related methods
WO2011061625A2 (en) 2009-11-19 2011-05-26 Solis Biodyne Compositions for increasing polypeptide stability and activity, and related methods
EP2905332A1 (en) 2009-11-19 2015-08-12 Solis Biodyne Compositions for increasing polypeptide stability and activity, and related methods
US11118169B2 (en) 2009-11-19 2021-09-14 Solis Biodyne Oü Compositions for increasing polypeptide stability and activity, and related methods
WO2011094430A2 (en) 2010-01-27 2011-08-04 Children's Medical Center Corporation Pro-angiogenic fragments of prominin-1 and uses thereof
US20130202673A1 (en) * 2010-03-16 2013-08-08 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
WO2011116132A1 (en) 2010-03-16 2011-09-22 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
US10111830B2 (en) * 2010-03-16 2018-10-30 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
US20130195951A1 (en) * 2010-03-16 2013-08-01 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
US20130195950A1 (en) * 2010-03-16 2013-08-01 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
US20130189342A1 (en) * 2010-03-16 2013-07-25 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
US10123971B2 (en) * 2010-03-16 2018-11-13 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
US11788142B2 (en) 2010-08-02 2023-10-17 Population Bio, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
US10059997B2 (en) 2010-08-02 2018-08-28 Population Bio, Inc. Compositions and methods for discovery of causative mutations in genetic disorders
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
WO2012085229A1 (en) 2010-12-22 2012-06-28 Pangaea Biotech, S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
WO2012109329A2 (en) 2011-02-08 2012-08-16 Children's Medical Center Corporation Methods for treatment of melanoma
US10159714B2 (en) 2011-02-16 2018-12-25 Intarcia Therapeutics, Inc. Compositions, devices and methods of use thereof for the treatment of cancers
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012113819A1 (en) 2011-02-23 2012-08-30 Pangaea Biotech, S.L. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
US9883944B2 (en) * 2011-02-28 2018-02-06 Scimotana Pty Ltd Surgical implant and method
US20140309744A1 (en) * 2011-02-28 2014-10-16 Scimotana Pty Ltd Surgical implant and method
US10603171B2 (en) 2011-02-28 2020-03-31 Scimotana Pty Ltd Surgical implant and method
US20180125661A1 (en) * 2011-02-28 2018-05-10 Scimotana Pty Ltd Surgical implant and method
EP3190108A1 (en) 2011-03-08 2017-07-12 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
US9205089B2 (en) 2011-04-29 2015-12-08 Massachusetts Institute Of Technology Layer processing for pharmaceuticals
WO2012149326A1 (en) * 2011-04-29 2012-11-01 Massachusetts Institute Of Technology Layer processing for pharmaceuticals
US11339439B2 (en) 2011-10-10 2022-05-24 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
WO2013054200A2 (en) 2011-10-10 2013-04-18 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US11180807B2 (en) 2011-11-04 2021-11-23 Population Bio, Inc. Methods for detecting a genetic variation in attractin-like 1 (ATRNL1) gene in subject with Parkinson's disease
WO2013067451A2 (en) 2011-11-04 2013-05-10 Population Diagnostics Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
US9120837B2 (en) 2012-01-06 2015-09-01 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
US9422251B2 (en) 2012-01-06 2016-08-23 Molecular Insight Pharmaceuticals, Inc. Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
US10407724B2 (en) 2012-02-09 2019-09-10 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US11174516B2 (en) 2012-02-09 2021-11-16 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US10149870B2 (en) 2012-02-29 2018-12-11 The General Hospital Corporation Compositions of microbiota and methods related thereto
US11590176B2 (en) 2012-02-29 2023-02-28 Johnson & Johnson Consumer Inc. Compositions of microbiota and methods related thereto
US10729732B2 (en) 2012-02-29 2020-08-04 Ethicon Endo Surgery, Inc. Compositions of microbiota and methods related thereto
EP2662079A1 (en) 2012-05-10 2013-11-13 Ordway Research Institute, Inc. Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells
US10507309B2 (en) 2012-06-01 2019-12-17 Surmodics, Inc. Apparatus and methods for coating medical devices
US10099041B2 (en) 2012-06-01 2018-10-16 Surmodics, Inc. Apparatus and methods for coating medical devices
US9623215B2 (en) 2012-06-01 2017-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
US9308355B2 (en) 2012-06-01 2016-04-12 Surmodies, Inc. Apparatus and methods for coating medical devices
US11008614B2 (en) 2012-09-14 2021-05-18 Population Bio, Inc. Methods for diagnosing, prognosing, and treating parkinsonism
WO2014043519A1 (en) 2012-09-14 2014-03-20 Population Diagnostics Inc. Methods and compositions for diagnosing, prognosing, and treating neurological conditions
US9976180B2 (en) 2012-09-14 2018-05-22 Population Bio, Inc. Methods for detecting a genetic variation in subjects with parkinsonism
US11618925B2 (en) 2012-09-27 2023-04-04 Population Bio, Inc. Methods and compositions for screening and treating developmental disorders
US10233495B2 (en) 2012-09-27 2019-03-19 The Hospital For Sick Children Methods and compositions for screening and treating developmental disorders
US10597721B2 (en) 2012-09-27 2020-03-24 Population Bio, Inc. Methods and compositions for screening and treating developmental disorders
US11712485B2 (en) 2013-01-14 2023-08-01 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
US10201624B2 (en) 2013-01-14 2019-02-12 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
US10086096B2 (en) 2013-01-14 2018-10-02 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
US10898598B2 (en) 2013-01-14 2021-01-26 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US10060934B2 (en) 2013-11-18 2018-08-28 Nanopharmaceuticals Llc Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
WO2015095767A1 (en) 2013-12-20 2015-06-25 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis and combinations thereof
WO2015105860A1 (en) 2014-01-07 2015-07-16 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
US9380813B2 (en) 2014-02-11 2016-07-05 Timothy McCullough Drug delivery system and method
US9408986B2 (en) * 2014-02-11 2016-08-09 Timothy McCullough Methods and devices using cannabis vapors
US10034990B2 (en) 2014-02-11 2018-07-31 Vapor Cartridge Technology Llc Drug delivery system and method
US10821240B2 (en) 2014-02-11 2020-11-03 Vapor Cartridge Technology Llc Methods and drug delivery devices using cannabis
US11395891B2 (en) 2014-02-11 2022-07-26 Vapor Cartridge Technology Llc Methods and delivery devices using herbal extracts
US10661036B2 (en) 2014-02-11 2020-05-26 Timothy McCullough Methods and delivery devices using herbal extracts
WO2015149016A2 (en) 2014-03-28 2015-10-01 University Of Washington Through Its Center For Commercialization Breast and ovarian cancer vaccines
US10213960B2 (en) 2014-05-20 2019-02-26 Massachusetts Institute Of Technology Plasticity induced bonding
US10703048B2 (en) 2014-05-20 2020-07-07 Massachusetts Institute Of Technology Plasticity induced bonding
WO2016011386A1 (en) 2014-07-18 2016-01-21 University Of Washington Cancer vaccine compositions and methods of use thereof
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
US11549145B2 (en) 2014-09-05 2023-01-10 Population Bio, Inc. Methods and compositions for inhibiting and treating neurological conditions
US10724096B2 (en) 2014-09-05 2020-07-28 Population Bio, Inc. Methods and compositions for inhibiting and treating neurological conditions
US10583080B2 (en) 2014-09-30 2020-03-10 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016054240A1 (en) 2014-09-30 2016-04-07 Sean Dalziel Fixed dose combinations for the treatment of viral diseases
US10842830B2 (en) 2014-10-31 2020-11-24 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US10675312B2 (en) 2014-10-31 2020-06-09 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US11364270B2 (en) 2014-10-31 2022-06-21 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US11213556B2 (en) 2014-10-31 2022-01-04 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US10668116B2 (en) 2014-10-31 2020-06-02 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US10842831B2 (en) 2014-10-31 2020-11-24 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US11278580B2 (en) 2014-10-31 2022-03-22 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
WO2016075578A1 (en) * 2014-11-16 2016-05-19 International Business Machines Corporation Helical coil delivery device for active agent
GB2553612B (en) * 2014-11-16 2020-03-04 Ibm Helical coil delivery device for active agent
GB2553612A (en) * 2014-11-16 2018-03-14 Ibm Helical coil delivery device for active agent
US9808608B2 (en) 2014-11-16 2017-11-07 International Business Machines Corporation Helical coil delivery device for active agent
JP2017536868A (en) * 2014-11-16 2017-12-14 インターナショナル・ビジネス・マシーンズ・コーポレーションInternational Business Machines Corporation Helical coil delivery device for active agents
WO2016149271A1 (en) 2015-03-19 2016-09-22 3-V Biosciences, Inc. Heterocyclic modulators of lipid synthesis
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
WO2017192743A1 (en) 2016-05-04 2017-11-09 Abilita Bio, Inc. Methods and platform for preparing multispanning membrane proteins
US10845367B2 (en) 2016-05-04 2020-11-24 Abilita Bio, Inc. Modified multispanning membrane polypeptides and methods of use thereof to screen therapeutic agents
US11840559B2 (en) 2016-05-16 2023-12-12 I2O Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
US10501517B2 (en) 2016-05-16 2019-12-10 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
US11214607B2 (en) 2016-05-16 2022-01-04 Intarcia Therapeutics Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD835783S1 (en) 2016-06-02 2018-12-11 Intarcia Therapeutics, Inc. Implant placement guide
USD962433S1 (en) 2016-06-02 2022-08-30 Intarcia Therapeutics, Inc. Implant placement guide
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD912249S1 (en) 2016-06-02 2021-03-02 Intarcia Therapeutics, Inc. Implant removal tool
US10201616B2 (en) 2016-06-07 2019-02-12 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists
US10695436B2 (en) 2016-06-07 2020-06-30 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with alpha V beta 3 integrin thyroid antagonists
US11654183B2 (en) 2017-01-03 2023-05-23 Intarcia Therapeutics, Inc. Methods comprising continuous administration of exenatide and co-administration of a drug
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US9827234B1 (en) 2017-02-03 2017-11-28 Osmotica Kereskedelmi és Szolgáltató KFT Dose-dumping resistant controlled release dosage form
US10563264B2 (en) 2017-02-03 2020-02-18 Pml Screening, Llc Methods for assessing risk of developing a viral disease using a genetic test
US9855258B1 (en) 2017-02-03 2018-01-02 Osmotica Kereskedelmi és Szolgáltató KFT Dose-dumping resistant controlled release dosage form
US10544463B2 (en) 2017-02-03 2020-01-28 Pml Screening, Llc Methods for assessing risk of developing a viral disease using a genetic test
US10265308B2 (en) 2017-02-03 2019-04-23 Osmotica Kereskedelmi Es Szolgaltato Kft Dose-dumping resistant controlled release dosage form
US10240205B2 (en) 2017-02-03 2019-03-26 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
US10695336B2 (en) 2017-02-03 2020-06-30 Osmotica Kereskedelmi Es Szolgaltato Kft Dose-dumping resistant controlled release dosage form
US9707217B1 (en) 2017-02-03 2017-07-18 Osmotica Kereskedelmi Es Szolgaltato Kft Dose-dumping resistant controlled release dosage form
US11913073B2 (en) 2017-02-03 2024-02-27 Pml Screening, Llc Methods for assessing risk of developing a viral disease using a genetic test
US10941448B1 (en) 2017-02-03 2021-03-09 The Universite Paris-Saclay Methods for assessing risk of developing a viral disease using a genetic test
WO2018158632A2 (en) 2017-02-03 2018-09-07 Population Bio, Inc. Methods for assessing risk of developing a viral disease using a genetic test
US11583558B2 (en) 2017-08-30 2023-02-21 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US11077082B2 (en) 2018-04-11 2021-08-03 Nanopharmaceuticals, Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US11332741B1 (en) 2018-06-29 2022-05-17 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
US11034954B2 (en) 2018-06-29 2021-06-15 Wuhan Neurophth Biological Technology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
US10961585B2 (en) 2018-08-08 2021-03-30 Pml Screening, Llc Methods for assessing risk of developing a viral of disease using a genetic test
US11913074B2 (en) 2018-08-08 2024-02-27 Pml Screening, Llc Methods for assessing risk of developing a viral disease using a genetic test
EP4177356A1 (en) 2018-08-08 2023-05-10 PML Screening, LLC Methods for assessing risk of developing a viral disease using a genetic test
WO2020033700A1 (en) 2018-08-08 2020-02-13 Pml Screening, Llc Mathods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
US11352645B2 (en) 2018-08-20 2022-06-07 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating Leber's hereditary optic neuropathy
US11628466B2 (en) 2018-11-29 2023-04-18 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
US11497249B2 (en) 2019-09-16 2022-11-15 Vapor Cartridge Technology Llc Drug delivery system with stackable substrates
US11357869B2 (en) 2019-12-09 2022-06-14 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy with NADH dehydrogenase proteins
US11186551B2 (en) 2020-04-29 2021-11-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved retention in tumors
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
WO2022195044A1 (en) * 2021-03-17 2022-09-22 Lts Lohmann Therapie-Systeme Ag Rolled oral thin films having a high level of active-ingredient loading
WO2023280157A1 (en) 2021-07-05 2023-01-12 武汉纽福斯生物科技有限公司 Construction and use of anti-vegf antibody in-vivo expression system
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Similar Documents

Publication Publication Date Title
US3625214A (en) Drug-delivery device
US3962414A (en) Structured bioerodible drug delivery device
US3867519A (en) Bioerodible drug delivery device
US3854480A (en) Drug-delivery system
US4439194A (en) Water and drug delivery system for suppository use
Langer Implantable controlled release systems
US3760806A (en) Helical osmotic dispenser with non-planar membrane
US3710795A (en) Drug-delivery device with stretched, rate-controlling membrane
EP0100424B1 (en) Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance
US3903880A (en) Intrauterine device for managing the reproductive process
US3995632A (en) Osmotic dispenser
Verma et al. Drug delivery technologies and future directions
US4721613A (en) Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
US3760805A (en) Osmotic dispenser with collapsible supply container
US4052505A (en) Ocular therapeutic system manufactured from copolymer
US4863744A (en) Intestine drug delivery
Robinson et al. Controlled drug delivery: fundamentals and applications
US4144317A (en) Device consisting of copolymer having acetoxy groups for delivering drugs
US3630200A (en) Ocular insert
US3826258A (en) Gradual release medicine carrier
US7914804B2 (en) Slow release pharmaceutical preparation and method of administering same
US3429308A (en) Method for administering drugs from a vehicle adhering by suction to the parabuccal cavity mucous membrane
Graham Polymeric inserts and implants for the controlled release of drugs
Sinha et al. Bioabsorbable polymers for implantable therapeutic systems
US20020164371A1 (en) Press coated, pulsatile drug delivery system suitable for oral administration